0001564590-18-012426.txt : 20180509 0001564590-18-012426.hdr.sgml : 20180509 20180509161756 ACCESSION NUMBER: 0001564590-18-012426 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20180331 FILED AS OF DATE: 20180509 DATE AS OF CHANGE: 20180509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: UNIVERSAL HEALTH REALTY INCOME TRUST CENTRAL INDEX KEY: 0000798783 STANDARD INDUSTRIAL CLASSIFICATION: REAL ESTATE INVESTMENT TRUSTS [6798] IRS NUMBER: 236858580 STATE OF INCORPORATION: MD FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-09321 FILM NUMBER: 18818508 BUSINESS ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH RD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 BUSINESS PHONE: 610-265-0688 MAIL ADDRESS: STREET 1: UNIVERSAL CORPORATE CTR STREET 2: 367 S GULPH ROAD CITY: KING OF PRUSSIA STATE: PA ZIP: 19406 10-Q 1 uht-10q_20180331.htm 10-Q uht-10q_20180331.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(MARK ONE)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2018

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                      

Commission file number 1-9321

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Exact name of registrant as specified in its charter)

 

 

MARYLAND

 

23-6858580

(State or other jurisdiction of

incorporation or organization)

 

(I. R. S. Employer

Identification No.)

 

 

 

UNIVERSAL CORPORATE CENTER

367 SOUTH GULPH ROAD

KING OF PRUSSIA, PENNSYLVANIA

 

19406

(Address of principal executive offices)

 

(Zip Code)

Registrant’s telephone number, including area code (610) 265-0688

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

Accelerated Filer

 

 

 

 

Non-accelerated filer

Smaller reporting company

 

 

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

Number of common shares of beneficial interest outstanding at April 30, 2018—13,735,629

 

 

 

 

 


UNIVERSAL HEALTH REALTY INCOME TRUST

INDEX

 

 

 

 

 

PAGE NO.

PART I. FINANCIAL INFORMATION (unaudited)

 

 

Item 1.

 

Financial Statements

 

 

 

 

Condensed Consolidated Statements of Income—Three Months Ended March 31, 2018 and 2017

 

3

 

 

Condensed Consolidated Statements of Comprehensive Income—Three Months Ended March 31, 2018 and 2017

 

4

 

 

Condensed Consolidated Balance Sheets—March 31, 2018 and December 31, 2017

 

5

 

 

Condensed Consolidated Statements of Cash Flows—Three Months Ended March 31, 2018 and 2017

 

6

 

 

Notes to Condensed Consolidated Financial Statements

 

7 through 15

Item 2.

 

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

16 through 26

Item 3.

 

Quantitative and Qualitative Disclosures About Market Risk

 

26

Item 4.

 

Controls and Procedures

 

26

PART II. OTHER INFORMATION

 

27

Item 6.

 

Exhibits

 

27

EXHIBIT INDEX

 

28

 

 

 

 

 

Signatures

 

29

 

 

 

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2018. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

As disclosed in this Quarterly Report, including in Note 2 to the Condensed Consolidated Financial Statements—Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions, a wholly-owned subsidiary of UHS (UHS of Delaware, Inc.) serves as our Advisor pursuant to the terms of an annually renewable Advisory Agreement dated December 24, 1986. Our officers are all employees of UHS through its wholly-owned subsidiary, UHS of Delaware, Inc. In addition, three of our hospital facilities are leased to subsidiaries of UHS and seventeen medical office buildings or free-standing emergency departments, that are either wholly or jointly-owned by us, include tenants which are subsidiaries of UHS. Any reference to “UHS” or “UHS facilities” in this report is referring to Universal Health Services, Inc.’s subsidiaries, including UHS of Delaware, Inc.

In this Quarterly Report, the term “revenues” does not include the revenues of the four unconsolidated limited liability companies (“LLCs”) in which we have various non-controlling equity interests ranging from 33% to 95%. We currently account for our share of the income/loss from these investments by the equity method (see Note 5 to the Condensed Consolidated Financial Statements included herein).

 

 

 

 


 

Part I. Financial Information

Item I. Financial Statements

Universal Health Realty Income Trust

Condensed Consolidated Statements of Income

For the Three Months Ended March 31, 2018 and 2017

(amounts in thousands, except per share amounts)

(unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2018

 

 

2017

 

Revenues:

 

 

 

 

 

 

 

 

Base rental - UHS facilities

 

$

4,176

 

 

$

4,080

 

Base rental - Non-related parties

 

 

10,327

 

 

 

9,970

 

Bonus rental - UHS facilities

 

 

1,326

 

 

 

1,288

 

Tenant reimbursements and other - Non-related parties

 

 

2,415

 

 

 

2,193

 

Tenant reimbursements and other - UHS facilities

 

 

295

 

 

 

219

 

 

 

 

18,539

 

 

 

17,750

 

Expenses:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,287

 

 

 

6,145

 

Advisory fees to UHS

 

 

904

 

 

 

866

 

Other operating expenses

 

 

5,208

 

 

 

4,705

 

Transaction costs

 

 

-

 

 

 

70

 

 

 

 

12,399

 

 

 

11,786

 

Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense, hurricane insurance recovery proceeds and gain

 

 

6,140

 

 

 

5,964

 

Equity in income of unconsolidated LLCs

 

 

429

 

 

 

1,077

 

     Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

4,535

 

 

 

-

 

     Hurricane business interruption insurance recovery proceeds

 

 

968

 

 

 

-

 

Gain on Arlington transaction

 

 

-

 

 

 

27,196

 

Interest expense, net

 

 

(2,468

)

 

 

(2,675

)

Net income

 

$

9,604

 

 

$

31,562

 

Basic earnings per share

 

$

0.70

 

 

$

2.32

 

Diluted earnings per share

 

$

0.70

 

 

$

2.32

 

 

 

 

 

 

 

 

 

 

Weighted average number of shares outstanding - Basic and Diluted

 

 

13,718

 

 

 

13,580

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

3


 

Universal Health Realty Income Trust

Condensed Consolidated Statements of Comprehensive Income

For the Three Months Ended March 31, 2018 and 2017

(dollar amounts in thousands)

(unaudited)

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2018

 

 

2017

 

Net income

 

$

9,604

 

 

$

31,562

 

Other comprehensive income/(loss):

 

 

 

 

 

 

 

 

Unrealized derivative gain/(loss) on interest rate caps

 

 

148

 

 

 

(18

)

Total other comprehensive income/(loss):

 

 

148

 

 

 

(18

)

Total comprehensive income

 

$

9,752

 

 

$

31,544

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

4


 

Universal Health Realty Income Trust

Condensed Consolidated Balance Sheets

(dollar amounts in thousands)

(unaudited)

 

 

 

March 31,

 

 

December 31,

 

 

 

2018

 

 

2017

 

Assets:

 

 

 

 

 

 

 

 

Real Estate Investments:

 

 

 

 

 

 

 

 

Buildings and improvements and construction in progress

 

$

549,465

 

 

$

546,634

 

Accumulated depreciation

 

 

(158,382

)

 

 

(153,379

)

 

 

 

391,083

 

 

 

393,255

 

Land

 

 

53,142

 

 

 

53,142

 

               Net Real Estate Investments

 

 

444,225

 

 

 

446,397

 

Investments in limited liability companies ("LLCs")

 

 

4,643

 

 

 

4,671

 

Other Assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

 

4,209

 

 

 

3,387

 

Base and bonus rent and other receivables from UHS

 

 

2,817

 

 

 

2,680

 

Rent receivable - other

 

 

6,690

 

 

 

6,422

 

Intangible assets (net of accumulated amortization of $25.7 million and

   $28.7 million at March 31, 2018 and December 31, 2017, respectively)

 

 

19,376

 

 

 

20,559

 

Deferred charges and other assets, net

 

 

7,625

 

 

 

5,892

 

               Total Assets

 

$

489,585

 

 

$

490,008

 

Liabilities:

 

 

 

 

 

 

 

 

Line of credit borrowings

 

$

175,000

 

 

$

181,050

 

Mortgage notes payable, non-recourse to us, net

 

 

70,781

 

 

 

75,359

 

Accrued interest

 

 

358

 

 

 

540

 

Accrued expenses and other liabilities

 

 

12,270

 

 

 

12,188

 

Dividends payable

 

 

9,134

 

 

 

-

 

Tenant reserves, deposits and deferred and prepaid rents

 

 

10,686

 

 

 

10,310

 

               Total Liabilities

 

 

278,229

 

 

 

279,447

 

Equity:

 

 

 

 

 

 

 

 

Preferred shares of beneficial interest,

   $.01 par value; 5,000,000 shares authorized;

   none issued and outstanding

 

 

-

 

 

 

-

 

Common shares, $.01 par value;

   95,000,000 shares authorized; issued and outstanding: 2018 - 13,735,611;

   2017 - 13,735,369

 

 

137

 

 

 

137

 

Capital in excess of par value

 

 

265,511

 

 

 

265,335

 

Cumulative net income

 

 

627,724

 

 

 

618,120

 

Cumulative dividends

 

 

(682,309

)

 

 

(673,175

)

Accumulated other comprehensive income

 

 

293

 

 

 

144

 

     Total Equity

 

 

211,356

 

 

 

210,561

 

               Total Liabilities and Equity

 

$

489,585

 

 

$

490,008

 

 

See accompanying notes to these condensed consolidated financial statements.

 

 

5


 

Universal Health Realty Income Trust

Condensed Consolidated Statement of Cash Flows

(dollar amounts in thousands)

(unaudited)

 

 

 

Three months ended March 31,

 

 

 

2018

 

 

2017

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

Net income

 

$

9,604

 

 

$

31,562

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

6,231

 

 

 

6,167

 

Amortization of debt premium

 

 

(10

)

 

 

(68

)

Stock-based compensation expense

 

 

119

 

 

 

127

 

Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

(4,535

)

 

 

 

Gain on Arlington transaction

 

 

 

 

 

(27,196

)

Changes in assets and liabilities:

 

 

 

 

 

 

 

 

Rent receivable

 

 

(405

)

 

 

(461

)

Accrued expenses and other liabilities

 

 

(367

)

 

 

(230

)

Tenant reserves, deposits and deferred and prepaid rents

 

 

296

 

 

 

64

 

Accrued interest

 

 

(182

)

 

 

(63

)

Leasing costs paid

 

 

(209

)

 

 

(250

)

Other, net

 

 

217

 

 

 

(158

)

Net cash provided by operating activities

 

 

10,759

 

 

 

9,494

 

Cash flows from investing activities:

 

 

 

 

 

 

 

 

Investments in LLCs

 

 

(369

)

 

 

(371

)

Repayments of advances made to LLC

 

 

 

 

 

216

 

Cash distributions in excess of income from LLCs

 

 

193

 

 

 

557

 

Additions to real estate investments, net

 

 

(1,987

)

 

 

(4,181

)

Cash proceeds received from divestiture of property

 

 

 

 

 

53,967

 

Restricted cash proceeds from divestiture of property

 

 

 

 

 

11,253

 

Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

4,535

 

 

 

 

Hurricane remediation payments

 

 

(192

)

 

 

 

Cash paid to acquire minority interests in majority-owned LLCs

 

 

 

 

 

(7,890

)

Net cash provided by investing activities

 

 

2,180

 

 

 

53,551

 

Cash flows from financing activities:

 

 

 

 

 

 

 

 

Net repayments on line of credit

 

 

(6,050

)

 

 

(31,600

)

Repayments of mortgage notes payable

 

 

(4,596

)

 

 

(11,174

)

Financing costs paid

 

 

(1,527

)

 

 

(35

)

Dividends paid

 

 

 

 

 

(8,907

)

Issuance of shares of beneficial interest, net

 

 

56

 

 

 

61

 

Net cash used in financing activities

 

 

(12,117

)

 

 

(51,655

)

Increase in cash, cash equivalents and restricted cash

 

 

822

 

 

 

11,390

 

Cash, cash equivalents and restricted cash,  beginning of period

 

 

3,387

 

 

 

3,930

 

Cash, cash equivalents and restricted cash, end of period

 

$

4,209

 

 

$

15,320

 

Supplemental disclosures of cash flow information:

 

 

 

 

 

 

 

 

Interest paid

 

$

2,525

 

 

$

2,673

 

 

See accompanying notes to these condensed consolidated financial statements.

 

6


 

UNIVERSAL HEALTH REALTY INCOME TRUST

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

March 31, 2018

(unaudited)

 

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2018. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2018, we had investments in four jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2017.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, Restricted Cash.

 

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each of the three hospital facilities leased to subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 22% and 23% of our consolidated revenues for the three months ended March 31, 2018 and 2017, respectively. In addition, we have seventeen medical office buildings (“MOBs”), or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, that include tenants which are subsidiaries of UHS.  The aggregate revenues generated from UHS-related tenants comprised approximately 31% of our consolidated revenues during each of the three-month periods ended March 31, 2018 and 2017.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

 

7


 

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2021

 

 

10

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b)

 

(a)

UHS has two 5-year renewal options at existing lease rates (through 2031).

(b)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  

In April, 2017, the recently constructed Henderson Medical Plaza MOB received its certificate of occupancy. Henderson Medical Plaza is located on the campus of the Henderson Hospital Medical Center, a newly constructed acute care hospital that is owned and operated by a subsidiary of UHS and was completed and opened during the fourth quarter of 2016.  A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two, ten-year renewal options at the lessee’s option at an adjusting lease rate. We have invested net cash of approximately $12.8 million on the development and construction of this MOB as of March 31, 2018.

Advisory Agreement:    UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. Our advisory fee is 0.70% of our average invested real estate assets, as derived from our consolidated balance sheet. In December of 2017, based upon a review of our advisory fee and other general and administrative expenses as compared to an industry peer group, the Advisory Agreement was renewed for 2018 pursuant to the same terms as the Advisory Agreement in place since 2013.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid at any time since our inception since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $904,000 and $866,000 for the three months ended March 31, 2018 and 2017, respectively, and were based upon average invested real estate assets of $517 million and $495 million for the three-month periods ended March 31, 2018 and 2017, respectively.  

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2018 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

8


 

Share Ownership: At each of March 31, 2018 and December 31, 2017, UHS owned 5.7%, of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 31% of our consolidated revenues during each of the three-month periods ended March 31, 2018 and 2017, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

(3) Dividends

Dividends:

We declared dividends of $9.1 million, or $.665 per share, during the first quarter of 2018, which were paid on April 2, 2018.  We declared and paid dividends of $8.9 million, or $.655 per share, during the first quarter of 2017.  

(4) Acquisitions and Dispositions

Three Months Ended March 31, 2018:

Acquisitions:

There were no acquisitions during the first three months of 2018.

Disposition:

There were no dispositions during the first three months of 2018.

Three Months Ended March 31, 2017:

Acquisitions:

 There were no acquisitions during the first three months of 2017.

Disposition:

During March, 2017, Arlington Medical Properties, LLC, a formerly jointly-owned limited liability company in which we held an 85% noncontrolling ownership interest, sold the real estate assets of St. Mary’s Professional Office Building (“St. Mary’s”) as part of a series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.  St. Mary’s is a multi-tenant medical office building located in Reno, Nevada.  A third party member owned the remaining 15% of Arlington Medical Properties LLC, which we acquired prior to the divestiture of St. Mary’s for a purchase price of $7.9 million. The divestiture of St. Mary’s generated an aggregate of approximately $57.3 million of net cash proceeds to us (approximately $11.3 million of which was held as restricted cash by a qualified 1031 exchange intermediary until the third quarter of 2017).  These proceeds, which were net of closing costs and the purchase price paid for the minority member’s ownership interest in the LLC, include repayment to us of a $21.4 million member loan.  Our results of operations for the three-month period ended March 31, 2017 included a net gain of $27.2 million (net of related transaction costs) recorded in connection with this transaction.  

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

In the Condensed Consolidated Statements of Cash Flows, distributions and equity in net income are presented net as cash flows from operating activities. Cumulative distributions received exceeding cumulative equity in earnings represent returns of investments and are classified as cash flows from investing activities in the Condensed Consolidated Statements of Cash Flows.

At March 31, 2018, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of March 31, 2018, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us

9


 

and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

 The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March 31, 2018:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March 31, 2018.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018.  This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March 31, 2018.

Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three months ended March 31, 2018 and 2017.  The three months ended March 31, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.  

 

 

 

Three Months Ended

March 31,

 

 

 

2018

 

 

2017

 

 

 

(amounts in thousands)

 

Revenues

 

$

2,462

 

 

$

3,583

 

Operating expenses

 

 

958

 

 

 

1,250

 

Depreciation and amortization

 

 

457

 

 

 

643

 

Interest, net

 

 

328

 

 

 

562

 

Net income

 

$

719

 

 

$

1,128

 

Our share of net income (a.)

 

$

429

 

 

$

1,077

 

 

(a.)

Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.   This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.  

 

10


 

Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of March 31, 2018 and December 31, 2017:

 

 

 

March 31,

2018

 

 

December 31,

2017

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

32,696

 

 

$

33,111

 

Other assets

 

 

3,298

 

 

 

3,560

 

Total assets

 

$

35,994

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

$

2,242

 

 

$

3,067

 

Mortgage notes payable, non-recourse to us

 

 

27,693

 

 

 

27,839

 

Equity

 

 

6,059

 

 

 

5,765

 

Total liabilities and equity

 

$

35,994

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

4,643

 

 

$

4,671

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,692

)

 

 

(1,895

)

Our share of equity in LLCs, net

 

$

2,951

 

 

$

2,776

 

   

As of March 31, 2018, and December 31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2018

 

 

12/31/2017

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan)

 

$

5,168

 

 

$

5,202

 

 

October, 2020

Grayson Properties (5.034% fixed rate mortgage loan)

 

 

14,125

 

 

 

14,191

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

8,400

 

 

 

8,446

 

 

December, 2024

 

 

$

27,693

 

 

$

27,839

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

(6) Recent Accounting Pronouncements

On January 1, 2018, we adopted ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, Restricted Cash, which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.  We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending March 31, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

March 31, 2018

 

 

March 31, 2017

 

Cash and cash equivalents

 

$

4,209

 

 

$

4,067

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

4,209

 

 

$

15,320

 

 

11


 

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America “GAAP”) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements.

 

On January 1, 2018, we adopted ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.   ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.  The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

 

Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.  We apply FASB ASC Topic 606, “Revenue from Contracts with Customers” with respect to tenant reimbursement and other property income, which totaled $2.7 million and $2.4 million for the three months ended March 31, 2018 and 2017, respectively. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.  Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.  Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.

(7) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2018, we entered into a replacement revolving credit agreement (“Credit Agreement”) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.  The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2018, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%.  

At March 31, 2018, we had $175.0 million of outstanding borrowings and $1.5 million of letters of credit outstanding under our Credit Agreement. We had $123.5 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2018.  There are no compensating balance requirements.  As disclosed below, subsequent to March 31, 2018, we repaid an aggregate of $17.6 million on two outstanding mortgages utilizing borrowings under our Credit Agreement.

12


 

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

March 31,

2018

 

Tangible net worth

 

> =$125,000

 

$

191,980

 

Total leverage

 

< 60%

 

 

39.7

%

Secured leverage

 

< 30%

 

 

11.0

%

Unencumbered leverage

 

< 60%

 

 

35.7

%

Fixed charge coverage

 

> 1.50x

 

3.9x

 

 

As indicated on the following table, we have ten mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2018 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Centennial Hills Medical Office Building floating rate

   mortgage loan (b.)

 

$

9,693

 

 

 

4.94

%

 

April, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan (c.)

 

 

7,922

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,599

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,010

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,077

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,912

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,974

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,199

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,397

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,363

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

71,146

 

 

 

 

 

 

 

     Less net financing fees

 

 

(652

)

 

 

 

 

 

 

     Plus net debt premium

 

 

287

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

70,781

 

 

 

 

 

 

 

 

13


 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

(b.)

Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.   

 

(c.)

Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.    

On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.  

The mortgages are secured by the real property of the buildings as well as property leases and rents. The ten mortgages outstanding as of March 31, 2018 had a combined fair value of approximately $71.1 million. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.

Financial Instruments:

During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.  This interest rate cap became effective in January, 2017 and expires in March, 2019. From inception through March 31, 2018, we received approximately $7,500 in payments made to us by the counterparties (all received during the first quarter of 2018) pursuant to the terms of these caps.

During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.  This interest rate cap became effective in October, 2016 and expires in March, 2019.  From inception through March 31, 2018, we received approximately $7,500 in payments made to us by the counterparties (all received during the first quarter of 2018) pursuant to the terms of these caps.

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered their own segment.

(9) Impact of Hurricane Harvey  

In late August, 2017, five of our medical office buildings listed below located in the Houston, Texas area incurred extensive water damage as a result of Hurricane Harvey. Through the first quarter of 2018, most of the space in these properties remained temporarily closed and non-operational as we continue to reconstruct and restore the properties to operational condition. Although we can provide no assurance on the ultimate re-opening dates, it is expected that all of the occupied space in the impacted buildings will be completed by June 30, 2018.

 

During the first quarter of 2018, pursuant to the terms of a global settlement with our commercial insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million.  We believe our aggregate insurance proceeds recoveries, which are net of applicable deductibles, will cover substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well as business interruption recoveries for the lost income related to each of these properties during the period they were/are non-operational.

14


 

 

Our financial results for the three months ended March 31, 2018 include approximately $968,000 of business interruption insurance recovery proceeds, covering the period of late August, 2017 through March 31, 2018, approximately $500,000 of which relates to 2017. These business interruption insurance recovery proceeds are included in net cash provided by operating activities in our condensed consolidated statement of cash flows for the three-month period ended March 31, 2018. Additionally, the three months ended March 31, 2018 includes approximately $4.5 million of hurricane insurance recoveries in excess of property damage write-downs, which are included in net cash provided by investing activities in our condensed consolidated statement of cash flows for the three-month period ended March 31, 2018.

 

Properties damaged and closed from Hurricane Harvey:

 

Cypresswood Professional Center – located in Spring, Texas and consisting of two MOBs.

 

Professional Buildings at King’s Crossing – located in Kingwood, Texas and consisting of two MOBs.

 

Kelsey-Seybold Clinic at King’s Crossing – located in Kingwood, Texas and consisting of one MOB.

15


 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Overview

We are a real estate investment trust (“REIT”) that commenced operations in 1986. We invest in healthcare and human service related facilities currently including acute care hospitals, rehabilitation hospitals, sub-acute facilities, surgery centers, free-standing emergency departments, childcare centers and medical/office buildings. As of April 30, 2018, we have sixty-eight real estate investments located in twenty states consisting of:

 

six hospital facilities consisting of three acute care, one rehabilitation and two sub-acute;

 

fifty-four medical/office buildings, including four owned by unconsolidated limited liability companies (“LLCs”)/limited liability partnerships (“LPs”);

 

four free-standing emergency departments (“FEDs”), and;

 

four pre-school and childcare centers.

Forward Looking Statements and Certain Risk Factors

You should carefully review all of the information contained in this Quarterly Report, and should particularly consider any risk factors that we set forth in this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the “SEC”). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. In some cases, you can identify those so-called “forward-looking statements” by words such as “may,” “will,” “should,” “could,” “would,” “predicts,” “potential,” “continue,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “appears,” “projects” and similar expressions, as well as statements in future tense. You should be aware that those statements are only our predictions. Actual events or results may differ materially. In evaluating those statements, you should specifically consider various factors, including the risks outlined herein and in our Annual Report on Form 10-K for the year ended December 31, 2017 in Item 1A Risk Factors and in Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations—Forward Looking Statements. Those factors may cause our actual results to differ materially from any of our forward-looking statements.

Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events, and is subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following:  

 

a substantial portion of our revenues are dependent upon one operator, Universal Health Services, Inc. (“UHS”). We cannot assure you that subsidiaries of UHS will renew the leases on our three acute care hospitals (which are scheduled to expire in December, 2021) and two FEDs at existing lease rates or fair market value lease rates. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital facilities and FEDs upon expiration of the lease terms, our future revenues and results of operations could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to these leases;

 

in certain of our markets, the general real estate market has been unfavorably impacted by increased competition/capacity and decreases in occupancy and rental rates which may adversely impact our operating results and the underlying value of our properties;

 

a number of legislative initiatives have recently been passed into law that may result in major changes in the health care delivery system on a national or state level to the operators of our facilities, including UHS. No assurances can be given that the implementation of these new laws will not have a material adverse effect on the business, financial condition or results of operations of our operators;

 

the potential indirect impact of the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”), signed into law on December 22, 2017, which makes significant changes to corporate and individual tax rates and calculation of taxes, which could potentially impact our tenants and jurisdictions, both positively and negatively, in which we do business, as well as the overall investment thesis for REITs;

 

a subsidiary of UHS is our Advisor and our officers are all employees of a wholly-owned subsidiary of UHS, which may create the potential for conflicts of interest;

 

lost revenues resulting from the exercise of purchase options, lease expirations and renewals and other restructuring;

16


 

 

our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund future growth of our business;

 

the outcome of known and unknown litigation, government investigations, and liabilities and other claims asserted against us, UHS or the other operators of our facilities. UHS and its subsidiaries are subject to pending legal actions, purported shareholder class actions and shareholder derivative cases, governmental investigations and regulatory actions. Since UHS comprised approximately 31% of our consolidated revenues for each of the three-month periods ended March 31, 2018 and 2017, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain and review the disclosures contained in the Legal Proceedings section of Universal Health Services, Inc.’s Forms 10-Q and 10-K, as publicly filed with the Securities and Exchange Commission. Those filings are the sole responsibility of UHS and are not incorporated by reference herein;

 

failure of UHS or the other operators of our hospital facilities to comply with governmental regulations related to the Medicare and Medicaid licensing and certification requirements could have a material adverse impact on our future revenues and the underlying value of the property;

 

the potential unfavorable impact on our business of deterioration in national, regional and local economic and business conditions, including a worsening of credit and/or capital market conditions, which may adversely affect our ability to obtain capital which may be required to fund the future growth of our business and refinance existing debt with near term maturities;

 

a deterioration in general economic conditions which could result in increases in the number of people unemployed and/or insured and likely increase the number of individuals without health insurance; as a result, the operators of our facilities may experience decreases in patient volumes which could result in decreased occupancy rates at our medical office buildings;

 

a worsening of the economic and employment conditions in the United States could materially affect the business of our operators, including UHS, which may unfavorably impact our future bonus rentals (on the UHS hospital facilities) and may potentially have a negative impact on the future lease renewal terms and the underlying value of the hospital properties;

 

real estate market factors, including without limitation, the supply and demand of office space and market rental rates, changes in interest rates as well as an increase in the development of medical office condominiums in certain markets;

 

the impact of property values and results of operations of severe weather conditions, including the effects of Hurricane Harvey on several of our properties in Texas;

 

government regulations, including changes in the reimbursement levels under the Medicare and Medicaid programs;

 

the issues facing the health care industry that affect the operators of our facilities, including UHS, such as: changes in, or the ability to comply with, existing laws and government regulations; unfavorable changes in the levels and terms of reimbursement by third party payors or government programs, including Medicare (including, but not limited to, the potential unfavorable impact of future reductions to Medicare reimbursements resulting from the Budget Control Act of 2011, as discussed below) and Medicaid (most states have reported significant budget deficits that have, in the past, resulted in the reduction of Medicaid funding to the operators of our facilities, including UHS); demographic changes; the ability to enter into managed care provider agreements on acceptable terms; an increase in uninsured and self-pay patients which unfavorably impacts the collectability of patient accounts; decreasing in-patient admission trends; technological and pharmaceutical improvements that may increase the cost of providing, or reduce the demand for, health care, and; the ability to attract and retain qualified medical personnel, including physicians;

 

in August, 2011, the Budget Control Act of 2011 (the “2011 Act”) was enacted into law. The 2011 Act imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. The 2011 Act provides for new spending on program integrity initiatives intended to reduce fraud and abuse under the Medicare program. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the “Joint Committee”), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. The Bipartisan Budget Act of 2015, enacted on November 2, 2015, continued the 2% reductions to Medicare reimbursement imposed under the 2011 Act.  We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what federal other deficit reduction initiatives

17


 

 

may be proposed by Congress going forward. We also cannot predict the effect these enactments will have on operators (including UHS), and, thus, our business;

 

in March, 2010, the Health Care and Education Reconciliation Act of 2010 and the Patient Protection and Affordable Care Act (the “ACA”) were enacted into law and created significant changes to health insurance coverage for U.S. citizens as well as material revisions to the federal Medicare and state Medicaid programs. The two combined primary goals of these acts are to provide for increased access to coverage for healthcare and to reduce healthcare-related expenses. Medicare, Medicaid and other health care industry changes are scheduled to be implemented at various times during this decade.  Initiatives to repeal the ACA, in whole or in part, to delay elements of implementation or funding, and to offer amendments or supplements to modify its provisions, have been persistent. The ultimate outcomes of legislative attempts to repeal or amend the ACA and legal challenges to the ACA are unknown.  Recent Congressional and Presidential election results created a political environment in which there have been repeated attempts to repeal or replace substantial portions of the ACA; 

 

Legislation has already been enacted that has repealed the individual mandate to obtain health insurance penalty that had been required by the ACA.  In addition, Congress is considering legislation that would, in material part: (i) eliminate the large employer mandates to provide health insurance coverage; (ii) permit insurers to impose a surcharge up to 30 percent on individuals who go uninsured for more than two months and then purchase coverage; (iii) provide tax credits towards the purchase of health insurance, with a phase-out of tax credits accordingly to income level; (iv) expand health savings accounts; (v) impose a per capita cap on federal funding of state Medicaid programs, or, if elected by a state, transition federal funding to block grants, and; (vi) permit states to seek a waiver of certain federal requirements that would allow such state to define essential health benefits differently from federal standards and that would allow certain commercial health plans to take health status, including pre-existing conditions, into account in setting premiums.   In addition to legislative changes, the Legislation can be significantly impacted by executive branch actions. In relevant part, President Trump has already taken executive actions: (i) requiring all federal agencies with authorities and responsibilities under the Legislation to “exercise all authority and discretion available to them to waiver, defer, grant exemptions, from, or delay” parts of the Legislation that place “unwarranted economic and regulatory burdens” on states, individuals or health care providers; (ii) directing the Department of Labor to enable the formation of health plans that would be exempt from certain Legislation essential health benefits requirements, and; (iii) eliminating cost-sharing reduction payments to insurers that would otherwise offset deductibles and other out-of-pocket expenses for health plan enrollees at or below 250 percent of the federal poverty level.  

It remains unclear what portions of the Legislation may remain, or whether any replacement or alternative programs may be created by any future legislation. Any such future repeal or replacement may have significant impact on the reimbursement for healthcare services generally, and may create reimbursement for services competing with the services offered by our hospitals. Accordingly, there can be no assurance that the adoption of any future federal or state healthcare reform legislation will not have a negative financial impact on our hospitals, including their ability to compete with alternative healthcare services funded by such potential legislation, or for our hospitals to receive payment for services;

 

there can be no assurance that if any of the announced or proposed changes described above are implemented there will not be negative financial impact on the operators of our hospitals, which material effects may include a potential decrease in the market for health care services or a decrease in the ability of the operators of our hospitals to receive reimbursement for health care services provided which could result in a material adverse effect on the financial condition or results of operations of the operators of our properties, and, thus, our business;

 

competition for our operators from other REITs;

 

the operators of our facilities face competition from other health care providers, including physician owned facilities and other competing facilities, including certain facilities operated by UHS but the real property of which is not owned by us. Such competition is experienced in markets including, but not limited to, McAllen, Texas, the site of our McAllen Medical Center, a 370-bed acute care hospital, and Riverside County, California, the site of our Southwest Healthcare System-Inland Valley Campus, a 130-bed acute care hospital;

 

changes in, or inadvertent violations of, tax laws and regulations and other factors than can affect REITs and our status as a REIT;

 

should we be unable to comply with the strict income distribution requirements applicable to REITs, utilizing only cash generated by operating activities, we would be required to generate cash from other sources which could adversely affect our financial condition;

 

our ownership interest in four LLCs/LPs in which we hold non-controlling equity interests. In addition, pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and the Trust, at any time, potentially subject to certain conditions, have the right to

18


 

 

make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member;

 

fluctuations in the value of our common stock, and;

 

other factors referenced herein or in our other filings with the Securities and Exchange Commission.

Given these uncertainties, risks and assumptions, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition, including the operating results of our lessees and the facilities leased to subsidiaries of UHS, could differ materially from those expressed in, or implied by, the forward-looking statements.

Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement.

Critical Accounting Policies and Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, Restricted Cash.

We consider our critical accounting policies to be those that require us to make significant judgments and estimates when we prepare our financial statements, including the following:

Purchase Accounting for Acquisition of Investments in Real Estate:  Purchase accounting is applied to the assets and liabilities related to all real estate investments acquired from third parties. In accordance with current accounting guidance, the fair value of the real estate acquired is allocated to the acquired tangible assets, consisting primarily of land, building and tenant improvements, and identified intangible assets and liabilities, consisting of the value of above-market and below-market leases, and acquired ground leases, based in each case on their fair values. Loan premiums, in the case of above market rate loans, or loan discounts, in the case of below market loans, are recorded based on the fair value of any loans assumed in connection with acquiring the real estate.

 

The fair values of the tangible assets of an acquired property are determined based on comparable land sales for land and replacement costs adjusted for physical and market obsolescence for the improvements. The fair values of the tangible assets of an acquired property are also determined by valuing the property as if it were vacant, and the “as-if-vacant” value is then allocated to land, building and tenant improvements based on management’s determination of the relative fair values of these assets. Management determines the as-if-vacant fair value of a property based on assumptions that a market participant would use, which is similar to methods used by independent appraisers. In addition, there is intangible value related to having tenants leasing space in the purchased property, which is referred to as in-place lease value. Such value results primarily from the buyer of a leased property avoiding the costs associated with leasing the property and also avoiding rent losses and unreimbursed operating expenses during the hypothetical lease-up period. Factors considered by management in performing these analyses include an estimate of carrying costs during the expected lease-up periods considering current market conditions and costs to execute similar leases. In estimating carrying costs, management includes real estate taxes, insurance and other operating expenses and estimates of lost rental revenue during the expected lease-up periods based on current market demand. Management also estimates costs to execute similar leases including leasing commissions, tenant improvements, legal and other related costs. The value of in-place leases are amortized to expense over the remaining initial terms of the respective leases.

 

In allocating the fair value of the identified intangible assets and liabilities of an acquired property, above-market and below-market in-place lease values are recorded based on the present value (using an interest rate which reflects the risks associated with the leases acquired) of the difference between (i) the contractual amounts to be paid pursuant to the in-place leases and (ii) estimated fair market lease rates from the perspective of a market participant for the corresponding in-place leases, measured, for above-market leases, over a period equal to the remaining non-cancelable term of the lease and, for below-market leases, over a period equal to the initial term plus any below market fixed rate renewal periods. The capitalized above-market lease values are amortized as a reduction of rental

19


 

income over the remaining non-cancelable terms of the respective leases. The capitalized below-market lease values, also referred to as acquired lease obligations, are amortized as an increase to rental income over the initial terms of the respective leases.

Asset Impairment:    We review each of our properties for indicators that its carrying amount may not be recoverable. Examples of such indicators may include a significant decrease in the market price of the property, a change in the expected holding period for the property, a significant adverse change in how the property is being used or expected to be used based on the underwriting at the time of acquisition, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of the property, or a history of operating or cash flow losses of the property. When such impairment indicators exist, we review an estimate of the future undiscounted net cash flows (excluding interest charges) expected to result from the real estate investment’s use and eventual disposition and compare that estimate to the carrying value of the property. We consider factors such as future operating income, trends and prospects, as well as the effects of leasing demand, competition and other factors. If our future undiscounted net cash flow evaluation indicates that we are unable to recover the carrying value of a real estate investment, an impairment loss is recorded to the extent that the carrying value exceeds the estimated fair value of the property. The evaluation of anticipated cash flows is highly subjective and is based in part on assumptions regarding future occupancy, rental rates and capital requirements that could differ materially from actual results in future periods. Since cash flows on properties considered to be long-lived assets to be held and used are considered on an undiscounted basis to determine whether the carrying value of a property is recoverable, our strategy of holding properties over the long-term directly decreases the likelihood of their carrying values not being recoverable and therefore requiring the recording of an impairment loss. If our strategy changes or market conditions otherwise dictate an earlier sale date, an impairment loss may be recognized and such loss could be material. If we determine that the asset fails the recoverability test, the affected assets must be reduced to their fair value.

 

We generally estimate the fair value of rental properties utilizing a discounted cash flow analysis that includes projections of future revenues, expenses and capital improvement costs that a market participant would use based on the highest and best use of the asset, which is similar to the income approach that is commonly utilized by appraisers. In certain cases, we may supplement this analysis by obtaining outside broker opinions of value or third party appraisals.

 

In considering whether to classify a property as held for sale, we consider factors such as whether management has committed to a plan to sell the property, the property is available for immediate sale in its present condition for a price that is reasonable in relation to its current value, the sale of the property is probable, and actions required for management to complete the plan indicate that it is unlikely that any significant changes will made to the plan.  If all the criteria are met, we classify the property as held for sale.  Upon being classified as held for sale, depreciation and amortization related to the property ceases and it is recorded at the lower of its carrying amount or fair value less cost to sell. The assets and related liabilities of the property are classified separately on the consolidated balance sheets for the most recent reporting period. Only those assets held for sale that constitute a strategic shift or that will have a major effect on our operations are classified as discontinued operations. 

An other than temporary impairment of an investment in an LLC is recognized when the carrying value of the investment is not considered recoverable based on evaluation of the severity and duration of the decline in value, including projected declines in cash flow. To the extent impairment has occurred, the excess carrying value of the asset over its estimated fair value is charged to income.

 

Federal Income Taxes:    No provision has been made for federal income tax purposes since we qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986, and intend to continue to remain so qualified.   To qualify as a REIT, we must meet certain organizational and operational requirements, including a requirement to distribute at least 90% of our annual REIT taxable income to shareholders. As a REIT, we generally will not be subject to federal, state or local income tax on income that we distribute as dividends to our shareholders. We have historically distributed, and intend to continue to distribute, 100% of our annual REIT taxable income to our shareholders.

We are subject to a federal excise tax computed on a calendar year basis. The excise tax equals 4% of the amount by which 85% of our ordinary income plus 95% of any capital gain income for the calendar year exceeds cash distributions during the calendar year, as defined. No provision for excise tax has been reflected in the financial statements as no tax was due.

Earnings and profits, which determine the taxability of dividends to shareholders, will differ from net income reported for financial reporting purposes due to the differences for federal tax purposes in the cost basis of assets and in the estimated useful lives used to compute depreciation and the recording of provision for investment losses.

Results of Operations

During the three-month period ended March 31, 2018, net income was $9.6 million, as compared to $31.6 million during the first quarter of 2017.  The $22.0 million decrease was primarily attributable to:

20


 

 

a $27.2 million decrease due to a gain recorded during the first quarter of 2017 in connection with our purchase of the minority interest in, and subsequent divestiture of, the St. Mary’s Professional Office Building (“Arlington transaction”);

 

a $4.5 million increase resulting from hurricane insurance recoveries in excess of property damage write-downs recorded during the first quarter of 2018;

 

a $968,000 increase resulting from hurricane-related business interruption insurance recovery proceeds received during the first quarter of 2018, covering the period of late August, 2017 through March 31,2018 (approximately $500,000 of which related to 2017);

 

a $207,000 increase due to decreased interest expense resulting primarily from the repayments of seven third-party mortgages (primarily between the second quarter of 2017 through the first quarter of 2018) utilizing funds borrowed under our revolving credit agreement which bear interest at a comparatively lower interest rate, partially offset by an increase in our average cost of funds under our revolving credit agreement as compared to the first quarter of 2017;

 

a $648,000 decrease in equity in income of LLCs, due primarily to the March, 2017 divestiture of St. Mary’s, and;

 

$176,000 of other combined net increases due to the increased net income generated at various properties, including the properties acquired during 2017.

Included in our other operating expenses are expenses related to the consolidated medical office buildings, which totaled $4.6 million and $4.1 million for the three-month periods ended March 31, 2018 and 2017, respectively.  The increase in operating expenses during the three-month periods ended March 31, 2018, as compared to the prior year periods, is partially due to the newly constructed medical office building which opened in April, 2017. A large portion of the expenses associated with our consolidated medical office buildings is passed on directly to the tenants either directly as tenant reimbursements of common area maintenance expenses or included in base rental amounts. Tenant reimbursements for operating expenses are accrued as revenue in the same period the related expenses are incurred and are included as tenant reimbursement revenue in our condensed consolidated statements of income.

Funds from operations (“FFO”) is a widely recognized measure of performance for Real Estate Investment Trusts (“REITs”). We believe that FFO and FFO per diluted share, which are non-GAAP financial measures, are helpful to our investors as measures of our operating performance. We compute FFO, as reflected on the attached Supplemental Schedules, in accordance with standards established by the National Association of Real Estate Investment Trusts (“NAREIT”), which may not be comparable to FFO reported by other REITs that do not compute FFO in accordance with the NAREIT definition, or that interpret the NAREIT definition differently than we interpret the definition. FFO adjusts for the effects of gains, such as gains on transactions and hurricane recovery proceeds in excess of damaged property write-downs. FFO does not represent cash generated from operating activities in accordance with GAAP and should not be considered to be an alternative to net income determined in accordance with GAAP. In addition, FFO should not be used as: (i) an indication of our financial performance determined in accordance with GAAP; (ii) an alternative to cash flow from operating activities determined in accordance with GAAP; (iii) a measure of our liquidity, or; (iv) an indicator of funds available for our cash needs, including our ability to make cash distributions to shareholders.

Below is a reconciliation of our reported net income to FFO for the three-month periods ended March 31, 2018 and 2017 (in thousands):

 

 

Three Months Ended

March 31,

 

 

 

2018

 

 

2017

 

Net income

 

$

9,604

 

 

$

31,562

 

Depreciation and amortization expense on consolidated

   investments

 

 

6,151

 

 

 

6,022

 

Depreciation and amortization expense on unconsolidated

   affiliates

 

 

271

 

 

 

426

 

Hurricane insurance recovery proceeds in excess of damaged property write-downs

 

 

(4,535

)

 

 

-

 

Gain on Arlington transaction

 

 

-

 

 

 

(27,196

)

Funds From Operations

 

$

11,491

 

 

$

10,814

 

Weighted average number of shares outstanding - Basic and Diluted

 

 

13,718

 

 

 

13,580

 

Funds From Operations per diluted share

 

$

0.84

 

 

$

0.80

 

 

 

 

 

 

 

 

 

 

21


 

Our FFO increased by $677,000, or $.04 per diluted share, during the three-month period ended March 31, 2018, as compared to the comparable period of 2017.  Our FFO were favorably impacted by approximately $968,000, or $.07 per diluted share, as a result of business interruption insurance recovery proceeds received during the first quarter of 2018, which included approximately $500,000, or $.04 per diluted share, of business interruption proceeds that covered the period of late August, 2017 through December 31, 2017.  

 

Hurricane Harvey Impact

In late August, 2017, five of our medical office buildings located in the Houston, Texas area, as mentioned below, incurred extensive water damage as a result of Hurricane Harvey. Through the first quarter of 2018, most of the space in these properties remained temporarily closed and non-operational as we continue to reconstruct and restore the properties to an operational condition. Although we can provide no assurance on the ultimate re-opening dates, it is expected that all of the occupied space in the impacted buildings will be completed by June 30, 2018.  

 

During the first quarter of 2018, pursuant to the terms of a global settlement with our commercial insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million. We believe our aggregate insurance proceeds recoveries, which are net of applicable deductibles, will cover substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well business interruption recoveries for the lost income related to each of these properties during the period they were/are non-operational.  

 

Properties damaged and temporarily closed from Hurricane Harvey:

 

Cypresswood Professional Center – located in Spring, Texas and consisting of two medical office buildings (“MOBs”) with an aggregate of approximately 40,000 rentable square feet.

 

Professional Buildings at King’s Crossing – located in Kingwood, Texas and consisting of two MOBs with an aggregate of approximately 24,300 rentable square feet.

 

Kelsey-Seybold Clinic at King’s Crossing – located in Kingwood, Texas and consisting of one MOB with approximately 20,500 rentable square feet.

 

Liquidity and Capital Resources

Net cash provided by operating activities

Net cash provided by operating activities was $10.8 million during the three-month period ended March 31, 2018 as compared to $9.5 million during the comparable period of 2017. The $1.3 million net increase was attributable to:

 

a favorable net change of $817,000 due to an increase in net income plus/minus the adjustments to reconcile net income to net cash provided by operating activities (depreciation and amortization, amortization of debt premium, stock-based compensation, hurricane insurance recovery proceeds in excess of damaged property write-downs, and gain on Arlington transaction);

 

a favorable change of $232,000 in tenant reserves, deposits and deferred and prepaid rents, and;

 

other combined net favorable changes of $216,000.

Net cash provided by investing activities

Net cash provided by investing activities was $2.2 million during the three months ended March 31, 2018 as compared to $53.6 million (including restricted cash of $11.3 million, as discussed below) during the three months ended March 31, 2017.

During the three-month period ended March 31, 2018, we funded: (i) $369,000 in equity investments in an unconsolidated LLC; (ii) $2.0 million in capital additions to real estate investments including tenant improvements at various MOBs, and; (iii) $192,000 of hurricane related remediation expenses  In addition, during the three-month period ended March 31, 2018, we received: (i) $4.5 million of hurricane insurance proceeds in excess of damaged property write-downs, and; (ii) received $193,000 of cash distributions in excess of income received from our unconsolidated LLCs.      

During the three-month period ended March 31, 2017, we funded: (i) $371,000 in equity investments in various unconsolidated LLCs; (ii) $4.2 million in capital additions to real estate investments primarily related to construction costs for the Henderson Medical Plaza MOB (this MOB opened in April, 2017), as well as tenant improvements at various MOBs; and (iii) $7.9 million paid to acquire the minority interest in a majority-owned LLC (Arlington Medical Properties). In addition, during the three-month period ended March 31, 2017, we received: (i) $54.0 million of net cash proceeds received in connection with the divestiture of St. Mary’s Professional Office Building, (net of closing costs and $11.3 million of restricted cash held by a 1031 exchange intermediary, as discussed below); (ii) $216,000 of installment repayments of an outstanding member loan that was provided by us to Arlington

22


 

Medical Properties, LLC, and; (iii) $557,000 of cash distributions in excess of income received from our unconsolidated LLCs.  Additionally, as a result of our January 1, 2018 adoption of ASU 2016-18, Restricted Cash, we recognized $11.3 million of restricted cash proceeds during the three-month period ended March 31, 2017 in connection with the divestiture of St. Mary’s Professional Office Building. This restricted cash was held by a 1031 exchange intermediary until the third quarter of 2017 at which time the majority of the cash was utilized to fund planned like-kind exchange acquisitions pursuant to Section 1031 of the IRS code.

Net cash used in financing activities

Net cash used in financing activities was $12.1 million during the three months ended March 31, 2018, as compared to $51.7 million during the three months ended March 31, 2017.

During the three-month period ended March 31, 2018, we paid: (i) $6.1 million of net borrowings on our revolving credit agreement; (ii) $4.6 million on mortgage notes payable that are non-recourse to us, including the repayment of $4.1 million related to a previously outstanding mortgage note payable on a property, that was funded utilizing borrowings under our revolving credit agreement, and; (iii) $1.5 million of financing costs related to the revolving credit agreement that was amended during the first quarter of 2018. Additionally, during the three months ended March 31, 2018, we received: (i) $56,000 of net cash from the issuance of shares of beneficial interest.

During the three-month period ended March 31, 2017, we paid: (i) $31.6 million of net borrowings on our revolving line of credit; (ii) $11.2 million on mortgages and other notes payable that are non-recourse to us, including the repayment of a $10.3 million mortgage which was refinanced during April, 2017; (iii) $35,000 of financing costs related to the revolving credit facility, and; (iv) $8.9 million of dividends.  Additionally, during the three months ended March 31, 2017, we received $61,000 of net cash from the issuance of shares of beneficial interest.

Additional cash flow and dividends paid information for the three-month periods ended March 31, 2018 and 2017:

As indicated on our condensed consolidated statement of cash flows, we generated net cash provided by operating activities of $10.8 million and $9.5 million during the three-month periods ended March 31, 2018 and 2017, respectively. As also indicated on our statement of cash flows, non-cash expenses including depreciation and amortization expense, amortization of debt premium, stock-based compensation expense, hurricane insurance recovery proceeds in excess of damaged property write-downs and gain on transaction (as applicable) are the primary differences between our net income and net cash provided by operating activities during each period. In addition, as reflected in the cash flows from investing activities section, we received $193,000 and $557,000 during the three-month periods ended March 31, 2018 and 2017, respectively, of cash distributions in excess of income from various unconsolidated LLCs which represents our share of the net cash flow distributions from these entities. The cash distributions in excess of income represent operating cash flows net of capital expenditures and debt repayments made by the LLCs.

We therefore generated $11.0 million and $10.1 million of net cash during the three months ended March 31, 2018 and 2017, respectively, related to the operating activities of our properties recorded on a consolidated and an unconsolidated basis. We declared dividends of $9.1 million during the three months ended March 31, 2018 (which were paid on April 2, 2018) and declared and paid dividends of $8.9 million during the three months ended March 31, 2017. During the first three months of 2018, the $11.0 million of net cash generated related to the operating activities of our properties was approximately $1.8 million greater than the $9.1 million of dividends declared during the first three months of 2018. During the first three months of 2017, the $10.1 million of net cash generated related to the operating activities of our properties was approximately $1.2 million greater than the $8.9 million of dividends declared and paid during the first three months of 2017.  

As indicated in the cash flows from investing activities and cash flows from financing activities sections of the statements of cash flows, there were various other sources and uses of cash during the three months ended March 31, 2018 and 2017.  From time to time, various other sources and uses of cash may include items such as investments and advances made to/from LLCs, additions to real estate investments, acquisitions/divestiture of properties, net borrowings/repayments of debt, and proceeds generated from the issuance of equity. Therefore, in any given period, the funding source for our dividend payments is not wholly dependent on the operating cash flow generated by our properties. Rather, our dividends as well as our capital reinvestments into our existing properties, acquisitions of real property and other investments are funded based upon the aggregate net cash inflows or outflows from all sources and uses of cash from the properties we own either in whole or through LLCs, as outlined above.

In determining and monitoring our dividend level on a quarterly basis, our management and Board of Trustees consider many factors in determining the amount of dividends to be paid each period. These considerations primarily include: (i) the minimum required amount of dividends to be paid in order to maintain our REIT status; (ii) the current and projected operating results of our properties, including those owned in LLCs, and; (iii) our future capital commitments and debt repayments, including those of our LLCs. Based upon the information discussed above, as well as consideration of projections and forecasts of our future operating cash flows,

23


 

management and the Board of Trustees have determined that our operating cash flows have been sufficient to fund our dividend payments. Future dividend levels will be determined based upon the factors outlined above with consideration given to our projected future results of operations.

We expect to finance all capital expenditures and acquisitions and pay dividends utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our existing $300 million revolving credit agreement (which had $123.5 million of available borrowing capacity, net of outstanding borrowings and letters of credit, as of March 31, 2018); (ii) borrowings under or refinancing of existing third-party debt pursuant to mortgage loan agreements entered into by our consolidated and unconsolidated LLCs/LPs; (iii) the issuance of equity, and/or; (iv) the issuance of other long-term debt.

We believe that our operating cash flows, cash and cash equivalents, available borrowing capacity under our revolving credit agreement and access to the capital markets provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months, including providing sufficient capital to allow us to make distributions necessary to enable us to continue to qualify as a REIT under Sections 856 to 860 of the Internal Revenue Code of 1986. In the event we need to access the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity.

Credit facilities and mortgage debt

 

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2018, we entered into a replacement revolving credit agreement (“Credit Agreement”) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.  The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2018, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%.  

At March 31, 2018, we had $175.0 million of outstanding borrowings and $1.5 million of letters of credit outstanding under our Credit Agreement. We had $123.5 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2018.  There are no compensating balance requirements.  As disclosed below, subsequent to March 31, 2018, we repaid an aggregate of $17.6 million on two outstanding mortgages utilizing borrowings under our Credit Agreement.  

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

24


 

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands): 

 

 

Covenant

 

March 31,

2018

 

Tangible net worth

 

> =$125,000

 

$

191,980

 

Total leverage

 

< 60%

 

 

39.7

%

Secured leverage

 

< 30%

 

 

11.0

%

Unencumbered leverage

 

< 60%

 

 

35.7

%

Fixed charge coverage

 

> 1.50x

 

3.9x

 

 

As indicated on the following table, we have ten mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2018 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands)(a)

 

 

Interest

Rate

 

 

Maturity

Date

Centennial Hills Medical Office Building floating rate

   mortgage loan (b.)

 

$

9,693

 

 

 

4.94

%

 

April, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan (c.)

 

 

7,922

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,599

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,010

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,077

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,912

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,974

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,199

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,397

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,363

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

71,146

 

 

 

 

 

 

 

     Less net financing fees

 

 

(652

)

 

 

 

 

 

 

     Plus net debt premium

 

 

287

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

70,781

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

(b.)

Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.  

 

(c.)

Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.      

On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.  

The mortgages are secured by the real property of the buildings as well as property leases and rents. The ten mortgages outstanding as of March 31, 2018 had a combined fair value of approximately $71.1 million. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.

 

Off Balance Sheet Arrangements

25


 

As of March 31, 2018, we are party to certain off balance sheet arrangements consisting of standby letters of credit and equity and debt financing commitments. Our outstanding letters of credit at March 31, 2018 totaled $1.5 million and were related to Centennial Hills Medical Properties.

Acquisition and Divestiture Activity

Please see Note 4 to the condensed consolidated financial statements for completed transactions.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Reference is made to Item 7A in our Annual Report on Form 10-K for the year ended December 31, 2017. There have been no material changes in the quantitative and qualitative disclosures during the first three months of 2018.

Item 4. Controls and Procedures

As of March 31, 2018, under the supervision and with the participation of our management, including the Trust’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), we performed an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “1934 Act”).

Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder.

There have been no changes in our internal control over financial reporting or in other factors during the first three months of 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

 

26


 

PART II. OTHER INFORMATION

UNIVERSAL HEALTH REALTY INCOME TRUST

Item 1A. Risk Factors

Our Annual Report on Form 10-K for the year ended December 31, 2017 includes a listing of risk factors to be considered by investors in our securities. There have been no material changes in our risk factors from those set forth in our Annual Report on Form 10-K for the year ended December 31, 2017.

Item 6. Exhibits

(a.) Exhibits:

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

27


 

EXHIBIT INDEX

 

Exhibit

No.

 

Description

 

 

 

  31.1

 

Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  31.2

 

Certification of the Chief Financial Officer pursuant to Rule 13a-14(a)/15(d)-14(a) under the Securities Exchange Act of 1934, as amended.

 

 

 

  32.1

 

Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

  32.2

 

Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

 

 

 

101.INS

 

XBRL Instance Document

 

 

 

101.SCH

 

XBRL Taxonomy Extension Schema Document

 

 

 

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document

 

 

 

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document

 

 

 

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

28


 

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: May 9, 2018

 

UNIVERSAL HEALTH REALTY INCOME TRUST

(Registrant)

 

 

 

 

 

/s/ Alan B. Miller 

 

 

Alan B. Miller,

 

 

Chairman of the Board,

President and Chief Executive Officer

(Principal Executive Officer)

 

 

 

 

 

/s/ Charles F. Boyle 

 

 

Charles F. Boyle, Vice President and Chief Financial Officer

(Principal Financial Officer)

 

29

EX-31.1 2 uht-ex311_8.htm EX-31.1 uht-ex311_8.htm

 

Exhibit 31.1

CERTIFICATION—Chief Executive Officer

I, Alan B. Miller, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2018

 

/s/ Alan B. Miller 

President and Chief Executive Officer

 

 

EX-31.2 3 uht-ex312_9.htm EX-31.2 uht-ex312_9.htm

 

Exhibit 31.2

CERTIFICATION—Chief Financial Officer

I, Charles F. Boyle, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Universal Health Realty Income Trust;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 9, 2018

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

 

 

EX-32.1 4 uht-ex321_6.htm EX-32.1 uht-ex321_6.htm

 

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Alan B. Miller, President and Chief Executive Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Alan B. Miller

President and Chief Executive Officer

May 9, 2018

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-32.2 5 uht-ex322_7.htm EX-32.2 uht-ex322_7.htm

 

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Universal Health Realty Income Trust (the “Trust”) on Form 10-Q for the quarter ended March 31, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Charles F. Boyle, Vice President and Chief Financial Officer of the Trust, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

(i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Trust at the end of, and for the period covered by, the Report.

 

/s/ Charles F. Boyle

Vice President and Chief Financial Officer

May 9, 2018

A signed original of this written statement required by Section 906 has been provided to the Trust and will be retained and furnished to the Securities and Exchange Commission or its staff upon request.

 

 

EX-101.INS 6 uht-20180331.xml XBRL INSTANCE DOCUMENT shares iso4217:USD iso4217:USD shares pure uht:Property uht:Time uht:RenewalOption uht:Acquisition uht:Option uht:MortgageLoan uht:Derivative uht:Segment uht:Building 0000798783 2018-01-01 2018-03-31 0000798783 2018-04-30 0000798783 2017-01-01 2017-03-31 0000798783 2018-03-31 0000798783 2017-12-31 0000798783 2016-12-31 0000798783 2017-03-31 0000798783 us-gaap:MinimumMember uht:UnconsolidatedLimitedLiabilitiesMember 2018-03-31 0000798783 us-gaap:MaximumMember uht:UnconsolidatedLimitedLiabilitiesMember 2018-03-31 0000798783 uht:MedicalOfficeBuildingsMember uht:LimitedLiabilityCompanyOrLimitedPartnerMember 2018-03-31 0000798783 uht:UniversalHealthServicesIncMember us-gaap:MinimumMember 2018-01-01 2018-03-31 0000798783 uht:UniversalHealthServicesIncMember us-gaap:MaximumMember 2018-01-01 2018-03-31 0000798783 uht:UniversalHealthServicesIncMember 2018-03-31 0000798783 uht:UniversalHealthServicesIncMember 2018-01-01 2018-03-31 0000798783 uht:UniversalHealthServicesIncMember us-gaap:AssetsLeasedToOthersMember 2018-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember 2017-01-01 2017-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2018-01-01 2018-03-31 0000798783 uht:RevenueMember us-gaap:CustomerConcentrationRiskMember uht:UniversalHealthServicesIncMember uht:TenantsMember 2017-01-01 2017-03-31 0000798783 uht:McAllenMedicalCenterMember 2018-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember 2018-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember 2018-03-31 0000798783 uht:McAllenMedicalCenterMember 2018-01-01 2018-03-31 0000798783 uht:WellingtonRegionalMedicalCenterMember 2018-01-01 2018-03-31 0000798783 uht:SouthwestHealthcareSystemInlandValleyCampusMember 2018-01-01 2018-03-31 0000798783 uht:McAllenMedicalCenterMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember us-gaap:MinimumMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-03-31 0000798783 uht:WellingtonRegionalMedicalCenterAndSouthwestHealthcareSystemMember us-gaap:MaximumMember uht:UniversalHealthServicesIncMember 2018-01-01 2018-03-31 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2017-04-01 2017-04-30 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2017-04-30 0000798783 uht:HendersonMedicalPlazaMember uht:UniversalHealthServicesIncMember 2018-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2018-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember us-gaap:MinimumMember 2018-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2018-01-01 2018-03-31 0000798783 uht:UniversalHealthServicesOfDelawareIncMember 2017-01-01 2017-03-31 0000798783 uht:UniversalHealthServicesIncMember 2017-12-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-03-12 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-03-01 2017-03-31 0000798783 uht:SaintMarysProfessionalOfficeBuildingMember 2017-03-31 0000798783 uht:SaintMarysProfessionalOfficeBuildingMember 2017-01-03 2017-09-30 0000798783 uht:SaintMarysProfessionalOfficeBuildingMember 2017-01-01 2017-03-31 0000798783 us-gaap:MinimumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2018-03-31 0000798783 us-gaap:MaximumMember uht:UnconsolidatedLimitedLiabilitiesOrLimitedPartnerMember 2018-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2018-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2018-03-31 0000798783 uht:SuburbanPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-03-31 0000798783 uht:BrunswickAssociatesMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-03-31 0000798783 uht:GraysonPropertiesMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-03-31 0000798783 uht:FTXMobPhaseTwoLPMember us-gaap:EquityMethodInvestmentsMember 2018-01-01 2018-03-31 0000798783 uht:BrunswickAssociatesMember 2018-03-31 0000798783 uht:GraysonPropertiesMember 2018-03-31 0000798783 uht:FTXMobPhaseTwoLPMember 2018-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2017-01-01 2017-03-31 0000798783 uht:ArlingtonMedicalPropertiesMember 2018-01-01 2018-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2018-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2018-03-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:GraysonPropertiesMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:BrunswickAssociatesMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember 2017-12-31 0000798783 us-gaap:EquityMethodInvestmentsMember uht:FTXMobPhaseTwoMember 2018-01-01 2018-03-31 0000798783 uht:FivePointZeroZeroPercentFixedRateMortgageLoanMember uht:FTXMobPhaseTwoMember 2018-03-31 0000798783 uht:FivePointZeroThreeFourPercentFixedRateMortgageLoanMember uht:GraysonPropertiesMember 2018-03-31 0000798783 uht:ThreePointSixFourPercentFixedRateMortgageLoanMember uht:BrunswickAssociatesMember 2018-03-31 0000798783 us-gaap:MinimumMember 2018-01-01 2018-03-31 0000798783 us-gaap:MaximumMember 2018-01-01 2018-03-31 0000798783 us-gaap:AccountingStandardsUpdate201409Member 2018-03-31 0000798783 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-03-31 0000798783 us-gaap:AccountingStandardsUpdate201409Member 2017-01-01 2017-03-31 0000798783 uht:RevolvingCreditAgreementMember 2018-03-31 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LetterOfCreditMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:ShortTermDebtMember 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember 2018-01-01 2018-03-31 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember us-gaap:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember us-gaap:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember uht:FederalFundsEffectiveRateMember us-gaap:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:MinimumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:MaximumMember 2018-03-27 2018-03-27 0000798783 uht:RevolvingCreditAgreementMember us-gaap:LondonInterbankOfferedRateLIBORMember 2018-01-01 2018-03-31 0000798783 uht:RevolvingCreditAgreementMember us-gaap:BaseRateMember 2018-01-01 2018-03-31 0000798783 us-gaap:SubsequentEventMember 2018-05-09 2018-05-09 0000798783 us-gaap:SubsequentEventMember 2018-05-09 0000798783 us-gaap:MaximumMember 2018-03-31 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2018-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2018-03-31 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2018-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2018-03-31 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2018-03-31 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2018-03-31 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2018-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2018-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2018-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2018-03-31 0000798783 uht:CentennialHillsMedicalOfficeBuildingOneMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:RosenbergChildrenMedicalPlazaFixedRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:VibraHospitalOfCorpusChristiFixedRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:SevenHundredShadowLaneAndGoldringMedicalOfficeBuildingMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:BRBMedicalOfficeBuildingMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:DesertValleyMedicalCenterFloatingRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:TwoSevenZeroFourNorthTenayaWayFixedRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:SummerlinHospitalMedicalOfficeBuildingThreeFixedRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:TuscanyProfessionalBuildingFixedRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:PhoenixChildrenEastValleyCareCenterFixedRateMortgageLoanMember 2018-01-01 2018-03-31 0000798783 uht:LomaVistaMedicalIncMember 2018-02-12 2018-02-13 0000798783 us-gaap:InterestRateCapMember 2016-06-30 0000798783 us-gaap:InterestRateCapMember 2016-09-30 0000798783 us-gaap:InterestRateCapMember 2016-04-01 2016-06-30 0000798783 us-gaap:InterestRateCapMember 2016-07-01 2016-09-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2016-06-30 0000798783 us-gaap:LondonInterbankOfferedRateLIBORMember us-gaap:InterestRateCapMember 2016-09-30 0000798783 us-gaap:InterestRateCapMember 2016-04-01 2018-03-31 0000798783 us-gaap:InterestRateCapMember 2016-07-01 2018-03-31 0000798783 uht:HoustonTexasMember uht:HurricaneHarveyExtensiveWaterDamageMember 2017-08-31 0000798783 uht:HurricaneHarveyMember 2018-01-01 2018-03-31 0000798783 uht:BusinessInterruptionMember uht:HurricaneHarveyMember 2017-09-01 2018-03-31 0000798783 uht:TwoThousandSeventeenBusinessInterruptionMember uht:HurricaneHarveyMember 2017-09-01 2017-12-31 0000798783 uht:BusinessInterruptionMember uht:HurricaneHarveyMember 2018-01-01 2018-03-31 0000798783 uht:SpringTexasMember uht:PropertiesDamagedAndClosedFromHurricaneHarveyMember uht:CypresswoodProfessionalCenterMember 2017-08-31 0000798783 uht:KingwoodTexasMember uht:PropertiesDamagedAndClosedFromHurricaneHarveyMember uht:ProfessionalBuildingsAtKingsCrossingMember 2017-08-31 0000798783 uht:KingwoodTexasMember uht:PropertiesDamagedAndClosedFromHurricaneHarveyMember uht:KelseySeyboldClinicAtKingsCrossingMember 2017-08-31 10-Q false 2018-03-31 2018 Q1 UHT UNIVERSAL HEALTH REALTY INCOME TRUST 0000798783 --12-31 Large Accelerated Filer 13735629 4176000 4080000 10327000 9970000 1326000 1288000 2415000 2193000 295000 219000 18539000 17750000 6287000 6145000 904000 866000 5208000 4705000 70000 12399000 11786000 6140000 5964000 429000 1077000 4535000 968000 27196000 -2468000 -2675000 9604000 31562000 0.70 2.32 0.70 2.32 13718000 13580000 148000 -18000 148000 -18000 9752000 31544000 549465000 546634000 158382000 153379000 391083000 393255000 53142000 53142000 444225000 446397000 4643000 4671000 4209000 3387000 2817000 2680000 6690000 6422000 19376000 20559000 7625000 5892000 489585000 490008000 175000000 181050000 70781000 75359000 358000 540000 12270000 12188000 9134000 10686000 10310000 278229000 279447000 137000 137000 265511000 265335000 627724000 618120000 682309000 673175000 293000 144000 211356000 210561000 489585000 490008000 25700000 28700000 0.01 0.01 5000000 5000000 0 0 0 0 0.01 0.01 95000000 95000000 13735611 13735369 13735611 13735369 6231000 6167000 -10000 -68000 119000 127000 405000 461000 -367000 -230000 296000 64000 182000 63000 209000 250000 -217000 158000 10759000 9494000 369000 371000 216000 193000 557000 -1987000 -4181000 53967000 11253000 4535000 192000 7890000 2180000 53551000 6050000 31600000 4596000 11174000 1527000 35000 8907000 56000 61000 -12117000 -51655000 822000 11390000 3387000 3930000 4209000 15320000 2525000 2673000 <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(1) General</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2018. In this Quarterly Report, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and the &#8220;Trust&#8221; refer to Universal Health Realty Income Trust and its subsidiaries.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In this Quarterly Report on Form 10-Q, the term &#8220;revenues&#8221; does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.&nbsp;&nbsp;As of March 31, 2018, we had investments in four jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2017.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, <font style="font-style:italic;">Restricted Cash</font>. </p></div> <div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(2) Relationship with Universal Health Services, Inc. (&#8220;UHS&#8221;) and Related Party Transactions</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Leases:<font style="font-style:normal;">&#160;We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each of the three hospital facilities leased to subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 22% and 23% of our consolidated revenues for the three months ended March 31, 2018 and 2017, respectively. In addition, we have seventeen medical office buildings (&#8220;MOBs&#8221;), or&#160;free-standing emergency departments (&#8220;FEDs&#8221;), that are either wholly or jointly-owned by us, that include tenants which are subsidiaries of UHS.&nbsp;&nbsp;The aggregate revenues generated from UHS-related tenants comprised approximately 31% of our consolidated revenues during each of the three-month periods ended March 31, 2018 and 2017. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December&#160;24, 1986 (the &#8220;Master Lease&#8221;), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month&#8217;s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i)&#160;purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii)&#160;renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Hospital Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has two 5-year renewal options at existing lease rates (through 2031).</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April, 2017, the recently constructed Henderson Medical Plaza MOB received its certificate of occupancy. Henderson Medical Plaza is located on the campus of the Henderson Hospital Medical Center, a newly constructed acute care hospital that is owned and operated by a subsidiary of UHS and was completed and opened during the fourth quarter of 2016.&nbsp;&nbsp;A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two, ten-year renewal options at the lessee&#8217;s option at an adjusting lease rate. We have invested net cash of approximately $12.8 million on the development and construction of this MOB as of March 31, 2018.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Advisory Agreement:&#160;&#160;&#160;&#160;<font style="font-style:normal;">UHS of Delaware, Inc. (the &#8220;Advisor&#8221;), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the &#8220;Advisory Agreement&#8221;) dated December&#160;24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the &#8220;Independent Trustees&#8221;). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December&#160;31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor&#8217;s performance has been satisfactory. Our advisory fee is 0.70% of our average invested real estate assets, as derived from our consolidated balance sheet. In December of 2017, based upon a review of our advisory fee and other general and administrative expenses as compared to an industry peer group, the Advisory Agreement was renewed for 2018 pursuant to the same terms as the Advisory Agreement in place since 2013.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid at any time since our inception since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $904,000 and $866,000 for the three months ended March&#160;31, 2018 and 2017, respectively, and were based upon average invested real estate assets of $517&#160;million and $495 million for the three-month periods ended March&#160;31, 2018 and 2017, respectively.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Officers and Employees:<font style="font-style:normal;"> Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March&#160;31, 2018 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Share Ownership:<font style="font-style:normal;"> At each of March&#160;31, 2018 and December&#160;31, 2017, UHS owned 5.7%, of our outstanding shares of beneficial interest.</font></p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SEC reporting requirements of UHS:<font style="font-style:normal;"> UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 31% of our consolidated revenues during each of the three-month periods ended March 31, 2018 and 2017, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC&#8217;s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.</font></p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(3) Dividends </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Dividends:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We declared dividends of $9.1 million, or $.665 per share, during the first quarter of 2018, which were paid on April 2, 2018.&nbsp;&nbsp;We declared and paid dividends of $8.9 million, or $.655 per share, during the first quarter of 2017.&nbsp;&nbsp;</p></div> <div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(4) Acquisitions and Dispositions</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2018:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no acquisitions during the first three months of 2018.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disposition:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no dispositions during the first three months of 2018.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended March&#160;31, 2017:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Acquisitions:</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;There were no acquisitions during the first three months of 2017.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Disposition:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During March, 2017, Arlington Medical Properties, LLC, a formerly jointly-owned limited liability company in which we held an 85% noncontrolling ownership interest, sold the real estate assets of St. Mary&#8217;s Professional Office Building (&#8220;St. Mary&#8217;s&#8221;) as part of a series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.&nbsp;&nbsp;St. Mary&#8217;s is a multi-tenant medical office building located in Reno, Nevada.&nbsp;&nbsp;A third party member owned the remaining 15% of Arlington Medical Properties LLC, which we acquired prior to the divestiture of St. Mary&#8217;s for a purchase price of $7.9 million. The divestiture of St. Mary&#8217;s generated an aggregate of approximately $57.3 million of net cash proceeds to us (approximately $11.3 million of which was held as restricted cash by a qualified 1031 exchange intermediary until the third quarter of 2017).&nbsp;&nbsp;These proceeds, which were net of closing costs and the purchase price paid for the minority member&#8217;s ownership interest in the LLC, include repayment to us of a $21.4 million member loan.&nbsp;&nbsp;Our results of operations for the three-month period ended March 31, 2017 included a net gain of $27.2 million (net of related transaction costs) recorded in connection with this transaction.&nbsp;&nbsp;</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(5) Summarized Financial Information of Equity Affiliates</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the Financial Accounting Standards Board&#8217;s (&#8220;FASB&#8221;) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.&nbsp;&nbsp;The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i)&#160;divestiture of property; (ii)&#160;annual budget approval, and; (iii)&#160;financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the Condensed Consolidated Statements of Cash Flows, distributions and equity in net income are presented net as cash flows from operating activities. Cumulative distributions received exceeding cumulative equity in earnings represent returns of investments and are classified as cash flows from investing activities in the Condensed Consolidated Statements of Cash Flows.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2018, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of March 31, 2018, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March&#160;31, 2018:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March&#160;31, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018.&nbsp;&nbsp;This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March&#160;31, 2018.</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three months ended March 31, 2018 and 2017.&nbsp;&nbsp;The three months ended March 31, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.&nbsp;&nbsp; </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,462</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">958</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">562</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,128</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,077</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.&nbsp;&nbsp; This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.&nbsp;&nbsp; </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of March 31, 2018 and December 31, 2017:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,696</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,298</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,560</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,994</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,242</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,693</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,059</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,765</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,994</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in LLCs before amounts included in</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,643</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,692</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,951</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,776</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-top:2pt;margin-bottom:0pt;margin-left:6.67%;text-indent:-3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, and December&#160;31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3/31/2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,168</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October, 2020</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,125</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,191</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (3.64% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,400</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,446</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,693</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.&#160;</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (&#8220;Offering Member&#8221;) to the other member(s) (&#8220;Non-Offering Member&#8221;) in which it either agrees to: (i)&#160;sell the entire ownership interest of the Offering Member to the Non-Offering Member (&#8220;Offer to Sell&#8221;) at a price as determined by the Offering Member (&#8220;Transfer Price&#8221;), or; (ii)&#160;purchase the entire ownership interest of the Non-Offering Member (&#8220;Offer to Purchase&#8221;) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i)&#160;purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii)&#160;sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(6) Recent Accounting Pronouncements</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU No. 2016-15, <font style="font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font>, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, <font style="font-style:italic;">Restricted Cash, </font>which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.&nbsp;&nbsp;We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending March 31, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.34%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,209</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,253</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Cash, Cash Equivalents and Restricted Cash</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,209</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,320</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02,<font style="font-style:italic;"> Leases</font> (&#8220;ASU 2016-02&#8221;), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America &#8220;GAAP&#8221;) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU 2014-09,&#160;<font style="font-style:italic;">Revenue From Contracts With Customers</font>&#160;(&#8220;ASU 2014-09&#8221;), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.&nbsp;&nbsp; ASU 2014-09 states that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.&nbsp;&nbsp;The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.&nbsp;&nbsp;We apply FASB ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; with respect to tenant reimbursement and other property income, which totaled $2.7 million and $2.4 million for the three months ended March 31, 2018 and 2017, respectively. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.&nbsp;&nbsp;Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.&nbsp;&nbsp;Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(7) Debt and Financial Instruments</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Debt:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Management routinely monitors and analyzes the Trust&#8217;s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.&nbsp;&nbsp;This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust&#8217;s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust&#8217;s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust&#8217;s growth.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On March 27, 2018, we entered into a replacement revolving credit agreement (&#8220;Credit Agreement&#8221;) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.&nbsp;&nbsp;The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.&nbsp;&nbsp;Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust&#8217;s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines &#8220;Base Rate&#8221; as the greater of: (a)&#160;the administrative agent&#8217;s prime rate; (b)&#160;the federal funds effective rate plus 1/2 of 1%, and; (c)&#160;one month LIBOR plus 1%.&nbsp;&nbsp;A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.&nbsp;&nbsp;At March 31, 2018, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%.&nbsp;&nbsp;</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At March 31, 2018, we had $175.0 million of outstanding borrowings and $1.5 million of letters of credit outstanding under our Credit Agreement. We had $123.5 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2018.&nbsp;&nbsp;There are no compensating balance requirements.&nbsp;&nbsp;As disclosed below, subsequent to March 31, 2018, we repaid an aggregate of $17.6 million on two outstanding mortgages utilizing borrowings under our Credit Agreement. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust&#8217;s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; =$125,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,980</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.7</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 30%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.7</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; 1.50x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As indicated on the following table, we have ten mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2018 (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Facility Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<font style="font-family:Calibri;">&#160;</font>thousands) (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centennial Hills Medical Office Building floating rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,693</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.94</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2018</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children&#8217;s Medical Plaza fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan (c.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,922</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.85</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,599</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July,&#160;2019</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,010</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,912</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2023</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,974</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,199</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2024</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,397</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2025</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children&#8217;s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,363</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,146</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Less net financing fees</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(652</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Plus net debt premium</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,781</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;">(a)</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">(b)</p></td> <td valign="top"> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement. &#160;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">(c)</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.&nbsp;&nbsp; &#160;</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.&nbsp;&nbsp; </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The mortgages are secured by the real property of the buildings as well as property leases and rents. The ten mortgages outstanding as of March 31, 2018 had a combined fair value of approximately $71.1 million. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Financial Instruments:</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.&nbsp;&nbsp;In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.&nbsp;&nbsp;This interest rate cap became effective in January, 2017 and expires in March, 2019. From inception through March 31, 2018, we received approximately $7,500 in payments made to us by the counterparties (all received during the first quarter of 2018) pursuant to the terms of these caps.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.&nbsp;&nbsp;In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.&nbsp;&nbsp;This interest rate cap became effective in October, 2016 and expires in March, 2019.&nbsp;&nbsp;From inception through March 31, 2018, we received approximately $7,500 in payments made to us by the counterparties (all received during the first quarter of 2018) pursuant to the terms of these caps.</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(8) Segment Reporting</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.&nbsp;&nbsp;No individual property meets the requirements necessary to be considered their own segment.</p></div> <div> <p style="margin-bottom:6pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">(9) Impact of Hurricane Harvey&nbsp;&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In late August, 2017, five of our medical office buildings listed below located in the Houston, Texas area incurred extensive water damage as a result of Hurricane Harvey. Through the first quarter of 2018, most of the space in these properties remained temporarily closed and non-operational as we continue to reconstruct and restore the properties to operational condition. Although we can provide no assurance on the ultimate re-opening dates, it is expected that all of the occupied space in the impacted buildings will be completed by June 30, 2018. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the first quarter of 2018, pursuant to the terms of a global settlement with our commercial insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million.&nbsp;&nbsp;We believe our aggregate insurance proceeds recoveries, which are net of applicable deductibles, will cover substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well as business interruption recoveries for the lost income related to each of these properties during the period they were/are non-operational.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our financial results for the three months ended March 31, 2018 include approximately $968,000 of business interruption insurance recovery proceeds, covering the period of late August, 2017 through March 31, 2018, approximately $500,000 of which relates to 2017. These business interruption insurance recovery proceeds are included in net cash provided by operating activities in our condensed consolidated statement of cash flows for the three-month period ended March 31, 2018. Additionally, the three months ended March 31, 2018 includes approximately $4.5 million of hurricane insurance recoveries in excess of property damage write-downs, which are included in net cash provided by investing activities in our condensed consolidated statement of cash flows for the three-month period ended March 31, 2018.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Properties damaged and closed from Hurricane Harvey:</font></p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Cypresswood Professional Center &#8211;<font style="font-weight:normal;"> located in Spring, Texas and consisting of two MOBs. </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Professional Buildings at King&#8217;s Crossing &#8211; <font style="font-weight:normal;">located in Kingwood, Texas and consisting of two MOBs. </font></p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:3.33%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Kelsey-Seybold Clinic at King&#8217;s Crossing &#8211; <font style="font-weight:normal;">located in Kingwood, Texas and consisting of one MOB.</font></p></td></tr></table></div></div> <div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU No. 2016-15, <font style="font-style:italic;">Classification of Certain Cash Receipts and Cash Payments</font>, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, <font style="font-style:italic;">Restricted Cash, </font>which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.&nbsp;&nbsp;We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending March 31, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.34%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,209</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,253</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Cash, Cash Equivalents and Restricted Cash</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,209</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,320</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued ASU 2016-02,<font style="font-style:italic;"> Leases</font> (&#8220;ASU 2016-02&#8221;), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America &#8220;GAAP&#8221;) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 1, 2018, we adopted ASU 2014-09,&#160;<font style="font-style:italic;">Revenue From Contracts With Customers</font>&#160;(&#8220;ASU 2014-09&#8221;), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.&nbsp;&nbsp; ASU 2014-09 states that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.&nbsp;&nbsp;The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.&nbsp;&nbsp;We apply FASB ASC Topic 606, &#8220;Revenue from Contracts with Customers&#8221; with respect to tenant reimbursement and other property income, which totaled $2.7 million and $2.4 million for the three months ended March 31, 2018 and 2017, respectively. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.&nbsp;&nbsp;Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.&nbsp;&nbsp;Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.26%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Hospital Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rent</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">End of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Term</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.5%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Renewal</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(years)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McAllen Medical Center</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,485,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wellington Regional Medical Center</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,030,000</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.26%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Southwest Healthcare System, Inland Valley Campus</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,648,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.46%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2021</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.5%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has two 5-year renewal options at existing lease rates (through 2031).</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).</p></td></tr></table></div></div> <div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March&#160;31, 2018:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.46%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Ownership</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Property Owned by LLC/LP</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suburban Properties</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">St. Matthews Medical Plaza II</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (a.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mid Coast Hospital MOB</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (b.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Texoma Medical Plaza</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.46%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (c.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forney Medical Plaza II</p></td> </tr> </table></div> <p style="border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-right:83.33%;text-indent:0%;font-size:6pt;font-family:Times New Roman;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March&#160;31, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018.&nbsp;&nbsp;This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March&#160;31, 2018.</p></td></tr></table></div></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three months ended March 31, 2018 and 2017.&nbsp;&nbsp;The three months ended March 31, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.&nbsp;&nbsp;</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Three Months Ended</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,462</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,583</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">958</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,250</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">457</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">643</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">328</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">562</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net income</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,128</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of net income (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">429</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,077</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a.)</font></p></td> <td valign="top"> <p style="margin-top:2pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.&nbsp;&nbsp; This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.&nbsp;&nbsp; </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">&#160;</p></div> <div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of March 31, 2018 and December 31, 2017:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(amounts in thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net property, including construction in progress</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,696</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33,111</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,298</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,560</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,994</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,242</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mortgage notes payable, non-recourse to us</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,693</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,059</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,765</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and equity</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,994</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,671</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Investments in LLCs before amounts included in</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,643</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,671</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Amounts included in accrued expenses and other liabilities</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,692</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,895</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our share of equity in LLCs, net</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,951</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,776</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of March 31, 2018, and December&#160;31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Mortgage Loan Balance (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of LLC/LP</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3/31/2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12/31/2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FTX MOB Phase II (5.00% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,168</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,202</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">October, 2020</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:54.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Grayson Properties (5.034% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,125</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,191</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">September, 2021</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Brunswick Associates (3.64% fixed rate mortgage loan)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,400</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,446</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December, 2024</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:54.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,693</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,839</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:18.2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (a.)</font></p></td> <td valign="top"> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity.&#160;</p></td></tr></table></div></div> <div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.34%; border-bottom:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.44%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.46%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March 31, 2017</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.34%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,209</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.08%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,067</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,253</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total Cash, Cash Equivalents and Restricted Cash</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.38%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,209</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.08%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.4%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,320</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Covenant</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">March&#160;31,</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tangible net worth</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; =$125,000</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">191,980</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39.7</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Secured leverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 30%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.0</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unencumbered leverage</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&lt; 60%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35.7</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fixed charge coverage</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&gt; 1.50x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9x</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div> <div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p> <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Facility Name</font></p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.54%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Balance</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in<font style="font-family:Calibri;">&#160;</font>thousands) (a.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Interest</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Rate</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maturity</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Centennial Hills Medical Office Building floating rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan (b.)</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,693</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.94</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%; border-top:solid 0.75pt #000000;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April, 2018</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rosenberg Children&#8217;s Medical Plaza fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan (c.)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,922</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.85</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">May,&#160;2018</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vibra Hospital-Corpus Christi fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,599</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.50</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">July,&#160;2019</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">700 Shadow Lane and Goldring MOBs fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,010</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.54</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">BRB Medical Office Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,077</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.27</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December,&#160;2022</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Desert Valley Medical Center fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,912</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January,&#160;2023</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2704 North Tenaya Way fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,974</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.95</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">November, 2023</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Summerlin Hospital Medical Office Building III fixed</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; rate mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,199</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.03</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">April,&#160;2024</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tuscan Professional Building fixed rate mortgage loan</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,397</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.56</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">June,&#160;2025</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Phoenix Children&#8217;s East Valley Care Center fixed rate</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; mortgage loan</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,363</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.95</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">January, 2030</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total, excluding net debt premium and net financing fees</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,146</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.7%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Less net financing fees</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(652</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.6%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp; Plus net debt premium</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">287</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> <tr> <td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.7%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total mortgages notes payable, non-recourse to us, net</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.54%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,781</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:17.6%; border-bottom:double 2.5pt transparent;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;">(a)</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;">(b)</p></td> <td valign="top"> <p style="margin-top:0pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement. &#160;</p></td></tr></table></div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:2.22%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td> <td valign="top" style="width:4.44%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;">(c)</p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.&nbsp;&nbsp; &#160;</p></td></tr></table></div></div> 0.33 0.95 4 P13Y P15Y 6 P5Y 3 0.22 0.23 17 0.31 0.31 P90D P180D P180D 3 5485000 3030000 2648000 2021-12 2021-12 2021-12 P10Y P10Y P10Y 2 P5Y 2031 2 P5Y 2022 2031 P75Y 2 P10Y 12800000 0.0070 0.20 0.15 0 0 904000 866000 517000000 495000000 0.057 0.057 0.665 0.655 2018-04-02 0 0 0 0.85 0.15 7900000 57300000 21400000 11300000 27200000 0.33 0.95 0.33 0.74 0.95 0.95 St. Matthews Medical Plaza II Mid Coast Hospital MOB Texoma Medical Plaza Forney Medical Plaza II 8400000 14100000 2100000 2500000 5200000 2462000 3583000 958000 1250000 457000 643000 328000 562000 719000 1128000 284000 0 32696000 33111000 3298000 3560000 35994000 36671000 2242000 3067000 27693000 27839000 6059000 5765000 35994000 36671000 1692000 1895000 2951000 2776000 5168000 14125000 8400000 27693000 5202000 14191000 8446000 27839000 2020-10 2021-09 2024-12 0.0500 0.05034 0.0364 P60D P90D 4067000 11253000 0 2700000 2400000 0 0 300000000 300000000 50000000 2022-03 40000000 30000000 2 50000000 one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. 0.0110 0.01 0.0135 0.0010 0.0035 the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%. 0.0050 0.0015 0.0035 0.0120 0.0020 0.0020 1500000 123500000 17600000 2 125000000 0.60 0.30 0.60 0.0150 191980000 0.397 0.110 0.357 0.039 10 9693000 7922000 2599000 6010000 6077000 4912000 6974000 13199000 4397000 9363000 0.0494 0.0485 0.0650 0.0454 0.0427 0.0362 0.0495 0.0403 0.0556 0.0395 2018-04 2018-05 2019-07 2022-06 2022-12 2023-01 2023-11 2024-04 2025-06 2030-01 71146000 652000 287000 9700000 7900000 4100000 71100000 11 75700000 76300000 1 1 30000000 30000000 115000 55000 2019-03-31 2019-03-31 0.0150 0.015 7500 7500 1 5 5500000 12500000 968000 500000 4500000 2 2 1 Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC. This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017. All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity. UHS has two 5-year renewal options at existing lease rates (through 2031). UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031). This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March 31, 2018. This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018. We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018. This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March 31, 2018. All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement. Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.   EX-101.SCH 7 uht-20180331.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statement of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100060 - Disclosure - General link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Dividends link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Acquisitions and Dispositions link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Summarized Financial Information of Equity Affiliates link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Recent Accounting Pronouncements link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Debt and Financial Instruments link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Impact of Hurricane Harvey link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Recent Accounting Pronouncements (Policies) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Recent Accounting Pronouncements (Tables) link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Debt and Financial Instruments (Tables) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - General - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Dividends - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Parenthetical) (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Segment Reporting - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Impact of Hurricane Harvey - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 uht-20180331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 uht-20180331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 uht-20180331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 11 uht-20180331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
Document and Entity Information - shares
3 Months Ended
Mar. 31, 2018
Apr. 30, 2018
Document And Entity Information [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Mar. 31, 2018  
Document Fiscal Year Focus 2018  
Document Fiscal Period Focus Q1  
Trading Symbol UHT  
Entity Registrant Name UNIVERSAL HEALTH REALTY INCOME TRUST  
Entity Central Index Key 0000798783  
Current Fiscal Year End Date --12-31  
Entity Filer Category Large Accelerated Filer  
Entity Common Stock, Shares Outstanding   13,735,629
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenues:    
Base rental - UHS facilities $ 4,176 $ 4,080
Base rental - Non-related parties 10,327 9,970
Bonus rental - UHS facilities 1,326 1,288
Tenant reimbursements and other - Non-related parties 2,415 2,193
Tenant reimbursements and other - UHS facilities 295 219
Revenues, Total 18,539 17,750
Expenses:    
Depreciation and amortization 6,287 6,145
Advisory fees to UHS 904 866
Other operating expenses 5,208 4,705
Transaction costs   70
Costs and Expenses, Total 12,399 11,786
Income before equity in income of unconsolidated limited liability companies ("LLCs"), interest expense, hurricane insurance recovery proceeds and gain 6,140 5,964
Equity in income of unconsolidated LLCs [1] 429 1,077
Hurricane insurance recovery proceeds in excess of damaged property write-downs 4,535  
Hurricane business interruption insurance recovery proceeds 968  
Gain on Arlington transaction   27,196
Interest expense, net (2,468) (2,675)
Net income $ 9,604 $ 31,562
Basic earnings per share $ 0.70 $ 2.32
Diluted earnings per share $ 0.70 $ 2.32
Weighted average number of shares outstanding - Basic and Diluted 13,718 13,580
[1] Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC. This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]    
Net income $ 9,604 $ 31,562
Other comprehensive income/(loss):    
Unrealized derivative gain/(loss) on interest rate caps 148 (18)
Total other comprehensive income/(loss): 148 (18)
Total comprehensive income $ 9,752 $ 31,544
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Real Estate Investments:    
Buildings and improvements and construction in progress $ 549,465 $ 546,634
Accumulated depreciation (158,382) (153,379)
Real Estate Investment Property, Net, Total 391,083 393,255
Land 53,142 53,142
Net Real Estate Investments 444,225 446,397
Investments in limited liability companies ("LLCs") 4,643 4,671
Other Assets:    
Cash and cash equivalents 4,209 3,387
Base and bonus rent and other receivables from UHS 2,817 2,680
Rent receivable - other 6,690 6,422
Intangible assets (net of accumulated amortization of $25.7 million and $28.7 million at March 31, 2018 and December 31, 2017, respectively) 19,376 20,559
Deferred charges and other assets, net 7,625 5,892
Total Assets 489,585 490,008
Liabilities:    
Line of credit borrowings 175,000 181,050
Mortgage notes payable, non-recourse to us, net 70,781 [1] 75,359
Accrued interest 358 540
Accrued expenses and other liabilities 12,270 12,188
Dividends payable 9,134  
Tenant reserves, deposits and deferred and prepaid rents 10,686 10,310
Total Liabilities 278,229 279,447
Equity:    
Preferred shares of beneficial interest, $.01 par value; 5,000,000 shares authorized; none issued and outstanding
Common shares, $.01 par value; 95,000,000 shares authorized; issued and outstanding: 2018 - 13,735,611; 2017 - 13,735,369 137 137
Capital in excess of par value 265,511 265,335
Cumulative net income 627,724 618,120
Cumulative dividends (682,309) (673,175)
Accumulated other comprehensive income 293 144
Total Equity 211,356 210,561
Total Liabilities and Equity $ 489,585 $ 490,008
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2018
Dec. 31, 2017
Statement Of Financial Position [Abstract]    
Intangible assets, accumulated amortization $ 25.7 $ 28.7
Preferred shares of beneficial interest, par value $ 0.01 $ 0.01
Preferred shares of beneficial interest, shares authorized 5,000,000 5,000,000
Preferred shares of beneficial interest, issued 0 0
Preferred shares of beneficial interest, outstanding 0 0
Common shares, par value $ 0.01 $ 0.01
Common shares, shares authorized 95,000,000 95,000,000
Common shares, issued 13,735,611 13,735,369
Common shares, outstanding 13,735,611 13,735,369
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Consolidated Statement of Cash Flows - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Cash flows from operating activities:    
Net income $ 9,604,000 $ 31,562,000
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 6,231,000 6,167,000
Amortization of debt premium (10,000) (68,000)
Stock-based compensation expense 119,000 127,000
Hurricane insurance recovery proceeds in excess of damaged property write-downs (4,535,000)  
Gain on Arlington transaction   (27,196,000)
Changes in assets and liabilities:    
Rent receivable (405,000) (461,000)
Accrued expenses and other liabilities (367,000) (230,000)
Tenant reserves, deposits and deferred and prepaid rents 296,000 64,000
Accrued interest (182,000) (63,000)
Leasing costs paid (209,000) (250,000)
Other, net 217,000 (158,000)
Net cash provided by operating activities 10,759,000 9,494,000
Cash flows from investing activities:    
Investments in LLCs (369,000) (371,000)
Repayments of advances made to LLC   216,000
Cash distributions in excess of income from LLCs 193,000 557,000
Additions to real estate investments, net (1,987,000) (4,181,000)
Cash proceeds received from divestiture of property 0 53,967,000
Restricted cash proceeds from divestiture of property   11,253,000
Hurricane insurance recovery proceeds in excess of damaged property write-downs 4,535,000  
Hurricane remediation payments (192,000)  
Cash paid to acquire minority interests in majority-owned LLCs   (7,890,000)
Net cash provided by investing activities 2,180,000 53,551,000
Cash flows from financing activities:    
Net repayments on line of credit (6,050,000) (31,600,000)
Repayments of mortgage notes payable (4,596,000) (11,174,000)
Financing costs paid (1,527,000) (35,000)
Dividends paid   (8,907,000)
Issuance of shares of beneficial interest, net 56,000 61,000
Net cash used in financing activities (12,117,000) (51,655,000)
Increase in cash, cash equivalents and restricted cash 822,000 11,390,000
Cash, cash equivalents and restricted cash, beginning of period 3,387,000 3,930,000
Cash, cash equivalents and restricted cash, end of period 4,209,000 15,320,000
Supplemental disclosures of cash flow information:    
Interest paid $ 2,525,000 $ 2,673,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
General
3 Months Ended
Mar. 31, 2018
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
General

(1) General

This Quarterly Report on Form 10-Q is for the quarter ended March 31, 2018. In this Quarterly Report, “we,” “us,” “our” and the “Trust” refer to Universal Health Realty Income Trust and its subsidiaries.

In this Quarterly Report on Form 10-Q, the term “revenues” does not include the revenues of the unconsolidated LLCs in which we have various non-controlling equity interests ranging from 33% to 95%.  As of March 31, 2018, we had investments in four jointly-owned LLCs/LPs which own medical office buildings, all of which are accounted for by the equity method (see Note 5). These LLCs are included in our financial statements for all periods presented on an unconsolidated basis since they are not variable interest entities for which we are the primary beneficiary, nor do we hold a controlling voting interest.

The financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the SEC and reflect all normal and recurring adjustments which, in our opinion, are necessary to fairly present results for the interim periods. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. It is suggested that these financial statements be read in conjunction with the financial statements, the notes thereto and accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2017.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. Certain prior period amounts on our statement of cash flows have been reclassified to conform to the current period presentation in connection with our adoption of ASU No. 2016-18, Restricted Cash.

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions
3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions

(2) Relationship with Universal Health Services, Inc. (“UHS”) and Related Party Transactions

Leases: We commenced operations in 1986 by purchasing properties of certain subsidiaries from UHS and immediately leasing the properties back to the respective subsidiaries. Most of the leases were entered into at the time we commenced operations and provided for initial terms of 13 to 15 years with up to six additional 5-year renewal terms. The current base rentals and lease and rental terms for each of the three hospital facilities leased to subsidiaries of UHS are provided below. The base rents are paid monthly and each lease also provides for additional or bonus rents which are computed and paid on a quarterly basis based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The three hospital leases with subsidiaries of UHS are unconditionally guaranteed by UHS and are cross-defaulted with one another.

The combined revenues generated from the leases on the UHS hospital facilities accounted for approximately 22% and 23% of our consolidated revenues for the three months ended March 31, 2018 and 2017, respectively. In addition, we have seventeen medical office buildings (“MOBs”), or free-standing emergency departments (“FEDs”), that are either wholly or jointly-owned by us, that include tenants which are subsidiaries of UHS.  The aggregate revenues generated from UHS-related tenants comprised approximately 31% of our consolidated revenues during each of the three-month periods ended March 31, 2018 and 2017.

Pursuant to the Master Lease Document by and among us and certain subsidiaries of UHS, dated December 24, 1986 (the “Master Lease”), which governs the leases of all hospital properties with subsidiaries of UHS, UHS has the option to renew the leases at the lease terms described below by providing notice to us at least 90 days prior to the termination of the then current term. UHS also has the right to purchase the respective leased facilities at the end of the lease terms or any renewal terms at the appraised fair market value. In addition, the Master Lease, as amended during 2006, includes a change of control provision whereby UHS has the right, upon one month’s notice should a change of control of the Trust occur, to purchase any or all of the three leased hospital properties listed below at their appraised fair market value. Additionally, UHS has rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer.

 

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2021

 

 

10

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b)

 

(a)

UHS has two 5-year renewal options at existing lease rates (through 2031).

(b)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

Management cannot predict whether the leases with subsidiaries of UHS, which have renewal options at existing lease rates or fair market value lease rates, or any of our other leases, will be renewed at the end of their lease term. If the leases are not renewed at their current rates or the fair market value lease rates, we would be required to find other operators for those facilities and/or enter into leases on terms potentially less favorable to us than the current leases. In addition, if subsidiaries of UHS exercise their options to purchase the respective leased hospital or FED facilities upon expiration of the lease terms, our future revenues could decrease if we were unable to earn a favorable rate of return on the sale proceeds received, as compared to the rental revenue currently earned pursuant to the these leases.  

In April, 2017, the recently constructed Henderson Medical Plaza MOB received its certificate of occupancy. Henderson Medical Plaza is located on the campus of the Henderson Hospital Medical Center, a newly constructed acute care hospital that is owned and operated by a subsidiary of UHS and was completed and opened during the fourth quarter of 2016.  A ground lease has been executed between the limited liability company that owns the MOB and a subsidiary of UHS, the terms of which include a seventy-five year lease term with two, ten-year renewal options at the lessee’s option at an adjusting lease rate. We have invested net cash of approximately $12.8 million on the development and construction of this MOB as of March 31, 2018.

Advisory Agreement:    UHS of Delaware, Inc. (the “Advisor”), a wholly-owned subsidiary of UHS, serves as Advisor to us under an Advisory Agreement (the “Advisory Agreement”) dated December 24, 1986. Pursuant to the Advisory Agreement, the Advisor is obligated to present an investment program to us, to use its best efforts to obtain investments suitable for such program (although it is not obligated to present any particular investment opportunity to us), to provide administrative services to us and to conduct our day-to-day affairs. All transactions between us and UHS must be approved by the Trustees who are unaffiliated with UHS (the “Independent Trustees”). In performing its services under the Advisory Agreement, the Advisor may utilize independent professional services, including accounting, legal, tax and other services, for which the Advisor is reimbursed directly by us. The Advisory Agreement may be terminated for any reason upon sixty days written notice by us or the Advisor. The Advisory Agreement expires on December 31 of each year; however, it is renewable by us, subject to a determination by the Independent Trustees, that the Advisor’s performance has been satisfactory. Our advisory fee is 0.70% of our average invested real estate assets, as derived from our consolidated balance sheet. In December of 2017, based upon a review of our advisory fee and other general and administrative expenses as compared to an industry peer group, the Advisory Agreement was renewed for 2018 pursuant to the same terms as the Advisory Agreement in place since 2013.

The average real estate assets for advisory fee calculation purposes exclude certain items from our consolidated balance sheet such as, among other things, accumulated depreciation, cash and cash equivalents, base and bonus rent receivables, deferred charges and other assets. The advisory fee is payable quarterly, subject to adjustment at year-end based upon our audited financial statements. In addition, the Advisor is entitled to an annual incentive fee equal to 20% of the amount by which cash available for distribution to shareholders for each year, as defined in the Advisory Agreement, exceeds 15% of our equity as shown on our consolidated balance sheet, determined in accordance with generally accepted accounting principles without reduction for return of capital dividends. The Advisory Agreement defines cash available for distribution to shareholders as net cash flow from operations less deductions for, among other things, amounts required to discharge our debt and liabilities and reserves for replacement and capital improvements to our properties and investments. No incentive fees were paid at any time since our inception since the incentive fee requirements were not achieved. Advisory fees incurred and paid (or payable) to UHS amounted to $904,000 and $866,000 for the three months ended March 31, 2018 and 2017, respectively, and were based upon average invested real estate assets of $517 million and $495 million for the three-month periods ended March 31, 2018 and 2017, respectively.  

Officers and Employees: Our officers are all employees of a wholly-owned subsidiary of UHS and although as of March 31, 2018 we had no salaried employees, our officers do typically receive annual stock-based compensation awards in the form of restricted stock. In special circumstances, if warranted and deemed appropriate by the Compensation Committee of the Board of Trustees, our officers may also receive one-time special compensation awards in the form of restricted stock and/or cash bonuses.

Share Ownership: At each of March 31, 2018 and December 31, 2017, UHS owned 5.7%, of our outstanding shares of beneficial interest.

SEC reporting requirements of UHS: UHS is subject to the reporting requirements of the SEC and is required to file annual reports containing audited financial information and quarterly reports containing unaudited financial information. Since the aggregate revenues generated from the UHS-related tenants comprised 31% of our consolidated revenues during each of the three-month periods ended March 31, 2018 and 2017, and since a subsidiary of UHS is our Advisor, you are encouraged to obtain the publicly available filings for Universal Health Services, Inc. from the SEC’s website. These filings are the sole responsibility of UHS and are not incorporated by reference herein.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
Dividends
3 Months Ended
Mar. 31, 2018
Equity [Abstract]  
Dividends

(3) Dividends

Dividends:

We declared dividends of $9.1 million, or $.665 per share, during the first quarter of 2018, which were paid on April 2, 2018.  We declared and paid dividends of $8.9 million, or $.655 per share, during the first quarter of 2017.  

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions and Dispositions
3 Months Ended
Mar. 31, 2018
Business Combinations [Abstract]  
Acquisitions and Dispositions

(4) Acquisitions and Dispositions

Three Months Ended March 31, 2018:

Acquisitions:

There were no acquisitions during the first three months of 2018.

Disposition:

There were no dispositions during the first three months of 2018.

Three Months Ended March 31, 2017:

Acquisitions:

 There were no acquisitions during the first three months of 2017.

Disposition:

During March, 2017, Arlington Medical Properties, LLC, a formerly jointly-owned limited liability company in which we held an 85% noncontrolling ownership interest, sold the real estate assets of St. Mary’s Professional Office Building (“St. Mary’s”) as part of a series of planned tax deferred like-kind exchange transactions pursuant to Section 1031 of the Internal Revenue Code.  St. Mary’s is a multi-tenant medical office building located in Reno, Nevada.  A third party member owned the remaining 15% of Arlington Medical Properties LLC, which we acquired prior to the divestiture of St. Mary’s for a purchase price of $7.9 million. The divestiture of St. Mary’s generated an aggregate of approximately $57.3 million of net cash proceeds to us (approximately $11.3 million of which was held as restricted cash by a qualified 1031 exchange intermediary until the third quarter of 2017).  These proceeds, which were net of closing costs and the purchase price paid for the minority member’s ownership interest in the LLC, include repayment to us of a $21.4 million member loan.  Our results of operations for the three-month period ended March 31, 2017 included a net gain of $27.2 million (net of related transaction costs) recorded in connection with this transaction.  

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summarized Financial Information of Equity Affiliates
3 Months Ended
Mar. 31, 2018
Equity Method Investments And Joint Ventures [Abstract]  
Summarized Financial Information of Equity Affiliates

(5) Summarized Financial Information of Equity Affiliates

In accordance with the Financial Accounting Standards Board’s (“FASB”) standards and guidance relating to accounting for investments and real estate ventures, we account for our unconsolidated investments in LLCs/LPs which we do not control using the equity method of accounting.  The third-party members in these investments have equal voting rights with regards to issues such as, but not limited to: (i) divestiture of property; (ii) annual budget approval, and; (iii) financing commitments. These investments, which represent 33% to 95% non-controlling ownership interests, are recorded initially at our cost and subsequently adjusted for our net equity in the net income, cash contributions to, and distributions from, the investments. Pursuant to certain agreements, allocations of sales proceeds and profits and losses of some of the LLC investments may be allocated disproportionately as compared to ownership interests after specified preferred return rate thresholds have been satisfied.

In the Condensed Consolidated Statements of Cash Flows, distributions and equity in net income are presented net as cash flows from operating activities. Cumulative distributions received exceeding cumulative equity in earnings represent returns of investments and are classified as cash flows from investing activities in the Condensed Consolidated Statements of Cash Flows.

At March 31, 2018, we have non-controlling equity investments or commitments in four jointly-owned LLCs/LPs which own MOBs. As of March 31, 2018, we accounted for these LLCs/LPs on an unconsolidated basis pursuant to the equity method since they are not variable interest entities and we do not have a controlling voting interest. The majority of these entities are joint-ventures between us and non-related parties that hold minority ownership interests in the entities. Each entity is generally self-sustained from a cash flow perspective and generates sufficient cash flow to meet its operating cash flow requirements and service the third-party debt (if applicable) that is non-recourse to us. Although there is typically no ongoing financial support required from us to these entities since they are cash-flow sufficient, we may, from time to time, provide funding for certain purposes such as, but not limited to, significant capital expenditures, leasehold improvements and debt financing. Although we are not obligated to do so, if approved by us at our sole discretion, additional cash fundings are typically advanced as equity or member loans. These entities maintain property insurance on the properties.

 The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March 31, 2018:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March 31, 2018.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018.  This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March 31, 2018.

Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three months ended March 31, 2018 and 2017.  The three months ended March 31, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.  

 

 

 

Three Months Ended

March 31,

 

 

 

2018

 

 

2017

 

 

 

(amounts in thousands)

 

Revenues

 

$

2,462

 

 

$

3,583

 

Operating expenses

 

 

958

 

 

 

1,250

 

Depreciation and amortization

 

 

457

 

 

 

643

 

Interest, net

 

 

328

 

 

 

562

 

Net income

 

$

719

 

 

$

1,128

 

Our share of net income (a.)

 

$

429

 

 

$

1,077

 

 

(a.)

Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.   This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.  

 

Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of March 31, 2018 and December 31, 2017:

 

 

 

March 31,

2018

 

 

December 31,

2017

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

32,696

 

 

$

33,111

 

Other assets

 

 

3,298

 

 

 

3,560

 

Total assets

 

$

35,994

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

$

2,242

 

 

$

3,067

 

Mortgage notes payable, non-recourse to us

 

 

27,693

 

 

 

27,839

 

Equity

 

 

6,059

 

 

 

5,765

 

Total liabilities and equity

 

$

35,994

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

4,643

 

 

$

4,671

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,692

)

 

 

(1,895

)

Our share of equity in LLCs, net

 

$

2,951

 

 

$

2,776

 

   

As of March 31, 2018, and December 31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2018

 

 

12/31/2017

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan)

 

$

5,168

 

 

$

5,202

 

 

October, 2020

Grayson Properties (5.034% fixed rate mortgage loan)

 

 

14,125

 

 

 

14,191

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

8,400

 

 

 

8,446

 

 

December, 2024

 

 

$

27,693

 

 

$

27,839

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

Pursuant to the operating and/or partnership agreements of the four LLCs/LPs in which we continue to hold non-controlling ownership interests, the third-party member and/or the Trust, at any time, potentially subject to certain conditions, have the right to make an offer (“Offering Member”) to the other member(s) (“Non-Offering Member”) in which it either agrees to: (i) sell the entire ownership interest of the Offering Member to the Non-Offering Member (“Offer to Sell”) at a price as determined by the Offering Member (“Transfer Price”), or; (ii) purchase the entire ownership interest of the Non-Offering Member (“Offer to Purchase”) at the equivalent proportionate Transfer Price. The Non-Offering Member has 60 to 90 days to either: (i) purchase the entire ownership interest of the Offering Member at the Transfer Price, or; (ii) sell its entire ownership interest to the Offering Member at the equivalent proportionate Transfer Price. The closing of the transfer must occur within 60 to 90 days of the acceptance by the Non-Offering Member.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recent Accounting Pronouncements
3 Months Ended
Mar. 31, 2018
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]  
Recent Accounting Pronouncements

(6) Recent Accounting Pronouncements

On January 1, 2018, we adopted ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, Restricted Cash, which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.  We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending March 31, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

March 31, 2018

 

 

March 31, 2017

 

Cash and cash equivalents

 

$

4,209

 

 

$

4,067

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

4,209

 

 

$

15,320

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America “GAAP”) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements.

 

On January 1, 2018, we adopted ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.   ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.  The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

 

Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.  We apply FASB ASC Topic 606, “Revenue from Contracts with Customers” with respect to tenant reimbursement and other property income, which totaled $2.7 million and $2.4 million for the three months ended March 31, 2018 and 2017, respectively. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.  Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.  Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt and Financial Instruments
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Debt and Financial Instruments

(7) Debt and Financial Instruments

Debt:

Management routinely monitors and analyzes the Trust’s capital structure in an effort to maintain the targeted balance among capital resources including the level of borrowings pursuant to our $300 million revolving credit agreement, the level of borrowings pursuant to non-recourse mortgage debt secured by the real property of our properties and our level of equity including consideration of additional equity issuances.  This ongoing analysis considers factors such as the current debt market and interest rate environment, the current/projected occupancy and financial performance of our properties, the current loan-to-value ratio of our properties, the Trust’s current stock price, the capital resources required for anticipated acquisitions and the expected capital to be generated by anticipated divestitures. This analysis, together with consideration of the Trust’s current balance of revolving credit agreement borrowings, non-recourse mortgage borrowings and equity, assists management in deciding which capital resource to utilize when events such as refinancing of specific debt components occur or additional funds are required to finance the Trust’s growth.

On March 27, 2018, we entered into a replacement revolving credit agreement (“Credit Agreement”) which, among other things, increased our borrowing capacity by $50 million to $300 million and extended the maturity date from our existing facility. The replacement Credit Agreement, which is scheduled to mature in March, 2022, includes a $40 million sublimit for letters of credit and a $30 million sub limit for swingline/short-term loans.  The Credit Agreement also provides for options to extend the maturity date for two additional six month periods. Additionally, the Credit Agreement includes an option to increase the total facility borrowing capacity up to an additional $50 million, subject to lender agreement.  Borrowings under the Credit Agreement are guaranteed by certain subsidiaries of the Trust. In addition, borrowings under the Credit Agreement are secured by first priority security interests in and liens on all equity interests in certain of the Trust’s wholly-owned subsidiaries. Borrowings made pursuant to the Credit Agreement will bear interest, at our option, at one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%. The Credit Agreement defines “Base Rate” as the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.  A facility fee of 0.15% to 0.35% will be charged on the total commitment of the Credit Agreement. The margins over LIBOR, Base Rate and the facility fee are based upon our total leverage ratio.  At March 31, 2018, the applicable margin over the LIBOR rate was 1.20%, the margin over the Base Rate was 0.20%, and the facility fee was 0.20%.  

At March 31, 2018, we had $175.0 million of outstanding borrowings and $1.5 million of letters of credit outstanding under our Credit Agreement. We had $123.5 million of available borrowing capacity, net of the outstanding borrowings and letters of credit outstanding as of March 31, 2018.  There are no compensating balance requirements.  As disclosed below, subsequent to March 31, 2018, we repaid an aggregate of $17.6 million on two outstanding mortgages utilizing borrowings under our Credit Agreement.

The Credit Agreement contains customary affirmative and negative covenants, including limitations on certain indebtedness, liens, acquisitions and other investments, fundamental changes, asset dispositions and dividends and other distributions. The Credit Agreement also contains restrictive covenants regarding the Trust’s ratio of total debt to total assets, the fixed charge coverage ratio, the ratio of total secured debt to total asset value, the ratio of total unsecured debt to total unencumbered asset value, and minimum tangible net worth, as well as customary events of default, the occurrence of which may trigger an acceleration of amounts outstanding under the Credit Agreement. We are in compliance with all of the covenants at March 31, 2018. We also believe that we would remain in compliance if the full amount of our commitment was borrowed.

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

March 31,

2018

 

Tangible net worth

 

> =$125,000

 

$

191,980

 

Total leverage

 

< 60%

 

 

39.7

%

Secured leverage

 

< 30%

 

 

11.0

%

Unencumbered leverage

 

< 60%

 

 

35.7

%

Fixed charge coverage

 

> 1.50x

 

3.9x

 

 

As indicated on the following table, we have ten mortgages, all of which are non-recourse to us, included on our condensed consolidated balance sheet as of March 31, 2018 (amounts in thousands):

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Centennial Hills Medical Office Building floating rate

   mortgage loan (b.)

 

$

9,693

 

 

 

4.94

%

 

April, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan (c.)

 

 

7,922

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,599

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,010

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,077

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,912

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,974

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,199

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,397

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,363

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

71,146

 

 

 

 

 

 

 

     Less net financing fees

 

 

(652

)

 

 

 

 

 

 

     Plus net debt premium

 

 

287

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

70,781

 

 

 

 

 

 

 

 

 

(a)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

(b)

Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.  

 

(c)

Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.    

On February 13, 2018, upon its maturity, a $4.1 million floating rate mortgage loan on the Sparks Medical Building/Vista Medical Terrace was fully repaid utilizing borrowings under our Credit Agreement.  

The mortgages are secured by the real property of the buildings as well as property leases and rents. The ten mortgages outstanding as of March 31, 2018 had a combined fair value of approximately $71.1 million. Changes in market rates on our fixed rate debt impacts the fair value of debt, but it has no impact on interest incurred or cash flow.

At December 31, 2017, we had eleven mortgages, all of which were non-recourse to us, included in our consolidated balance sheet. The combined outstanding balance of these eleven mortgages was $75.7 million and had a combined fair value of approximately $76.3 million.

Financial Instruments:

During the second quarter of 2016, we entered into an interest rate cap on the total notional amount of $30 million whereby we paid a premium of $115,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.50% and one-month LIBOR if one-month LIBOR rises above 1.50% during the term of the cap.  This interest rate cap became effective in January, 2017 and expires in March, 2019. From inception through March 31, 2018, we received approximately $7,500 in payments made to us by the counterparties (all received during the first quarter of 2018) pursuant to the terms of these caps.

During the third quarter of 2016, we entered into an additional interest rate cap agreement on a total notional amount of $30 million whereby we paid a premium of $55,000.  In exchange for the premium payment, the counterparties agreed to pay us the difference between 1.5% and one-month LIBOR if one-month LIBOR rises above 1.5% during the term of the cap.  This interest rate cap became effective in October, 2016 and expires in March, 2019.  From inception through March 31, 2018, we received approximately $7,500 in payments made to us by the counterparties (all received during the first quarter of 2018) pursuant to the terms of these caps.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting
3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Segment Reporting

(8) Segment Reporting

Our primary business is investing in and leasing healthcare and human service facilities through direct ownership or through joint ventures, which aggregate into a single reportable segment. We actively manage our portfolio of healthcare and human service facilities and may from time to time make decisions to sell lower performing properties not meeting our long-term investment objectives. The proceeds of sales are typically reinvested in new developments or acquisitions, which we believe will meet our planned rate of return. It is our intent that all healthcare and human service facilities will be owned or developed for investment purposes. Our revenue and net income are generated from the operation of our investment portfolio.

Our portfolio is located throughout the United States, however, we do not distinguish or group our operations on a geographical basis for purposes of allocating resources or measuring performance. We review operating and financial data for each property on an individual basis; therefore, we define an operating segment as our individual properties. Individual properties have been aggregated into one reportable segment based upon their similarities with regard to both the nature and economics of the facilities, tenants and operational processes, as well as long-term average financial performance.  No individual property meets the requirements necessary to be considered their own segment.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
Impact of Hurricane Harvey
3 Months Ended
Mar. 31, 2018
Extraordinary And Unusual Items [Abstract]  
Impact of Hurricane Harvey

(9) Impact of Hurricane Harvey  

In late August, 2017, five of our medical office buildings listed below located in the Houston, Texas area incurred extensive water damage as a result of Hurricane Harvey. Through the first quarter of 2018, most of the space in these properties remained temporarily closed and non-operational as we continue to reconstruct and restore the properties to operational condition. Although we can provide no assurance on the ultimate re-opening dates, it is expected that all of the occupied space in the impacted buildings will be completed by June 30, 2018.

 

During the first quarter of 2018, pursuant to the terms of a global settlement with our commercial insurance carrier, we received $5.5 million of additional insurance recovery proceeds bringing the aggregate hurricane-related insurance recoveries to $12.5 million.  We believe our aggregate insurance proceeds recoveries, which are net of applicable deductibles, will cover substantially all of the costs incurred related to the remediation, repair and reconstruction of each of these properties as well as business interruption recoveries for the lost income related to each of these properties during the period they were/are non-operational.

 

Our financial results for the three months ended March 31, 2018 include approximately $968,000 of business interruption insurance recovery proceeds, covering the period of late August, 2017 through March 31, 2018, approximately $500,000 of which relates to 2017. These business interruption insurance recovery proceeds are included in net cash provided by operating activities in our condensed consolidated statement of cash flows for the three-month period ended March 31, 2018. Additionally, the three months ended March 31, 2018 includes approximately $4.5 million of hurricane insurance recoveries in excess of property damage write-downs, which are included in net cash provided by investing activities in our condensed consolidated statement of cash flows for the three-month period ended March 31, 2018.

 

Properties damaged and closed from Hurricane Harvey:

 

Cypresswood Professional Center – located in Spring, Texas and consisting of two MOBs.

 

Professional Buildings at King’s Crossing – located in Kingwood, Texas and consisting of two MOBs.

 

Kelsey-Seybold Clinic at King’s Crossing – located in Kingwood, Texas and consisting of one MOB.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recent Accounting Pronouncements (Policies)
3 Months Ended
Mar. 31, 2018
Accounting Policies [Abstract]  
Recent Accounting Pronouncements

On January 1, 2018, we adopted ASU No. 2016-15, Classification of Certain Cash Receipts and Cash Payments, which adds or clarifies guidance of the classification of certain cash receipts and payments in the statement of cash flows, and ASU 2016-18, Restricted Cash, which requires an entity to show the changes in total cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows.  We adopted these ASUs by applying a retrospective transition method which requires a reclassification of our Consolidated Statement of Cash Flows for the period ending March 31, 2017. The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

March 31, 2018

 

 

March 31, 2017

 

Cash and cash equivalents

 

$

4,209

 

 

$

4,067

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

4,209

 

 

$

15,320

 

 

In February 2016, the FASB issued ASU 2016-02, Leases (“ASU 2016-02”), which introduces a lessee model that brings most leases on the balance sheet and, among other changes, eliminates the requirement in current Generally Accepted Accounting Principles in the United States of America “GAAP”) for an entity to use bright-line tests in determining lease classification. The FASB also issued an Exposure Draft on January 5, 2018 proposing to amend ASU 2016-02, which would provide lessors with a practical expedient, by class of underlying assets, to not separate non-lease components from the related lease components and, instead, to account for those components as a single lease component, if certain criteria are met. ASU 2016-02 and the related Exposure Draft are not effective for us until January 1, 2019, with early adoption permitted. We are continuing to evaluate this guidance and the impact to us, as both lessor and lessee, on our Consolidated Financial Statements.

 

On January 1, 2018, we adopted ASU 2014-09, Revenue From Contracts With Customers (“ASU 2014-09”), which outlines a comprehensive model for entities to use in accounting for revenue arising from contracts with customers. We adopted the standard on January 1, 2018, using the modified retrospective approach, which requires a cumulative-effect adjustment to equity as of the date of adoption.   ASU 2014-09 states that “an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.” While ASU 2014-09 specifically references contracts with customers, it may apply to certain other transactions such as the sale of real estate or equipment.  The adoption of this standard did not have a significant impact on our consolidated financial statements and no cumulative adjustment was recorded upon adoption, as a substantial portion of our revenue consists of rental income from leasing arrangements, which is specifically excluded from ASU 2014-09.

 

Our revenues consist primarily of rentals received from tenants, which are comprised of minimum rent (base rentals) and bonus rentals and reimbursements from tenants for their pro-rata share of expenses such as common area maintenance costs, real estate taxes and utilities.  We apply FASB ASC Topic 606, “Revenue from Contracts with Customers” with respect to tenant reimbursement and other property income, which totaled $2.7 million and $2.4 million for the three months ended March 31, 2018 and 2017, respectively. Tenant reimbursements for operating expenses are accrued as revenue and generally due monthly from tenants.  Since payments with respect to tenant reimbursement income are generally due monthly, no contract assets or liabilities have been recognized.  Revenue consisting of rental income from leasing arrangements are specifically excluded from FASB ASC Topic 606.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables)
3 Months Ended
Mar. 31, 2018
Related Party Transactions [Abstract]  
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities

The table below details the existing lease terms and renewal options for our three acute care hospitals operated by wholly-owned subsidiaries of UHS:

 

Hospital Name

 

Annual

Minimum

Rent

 

 

End of

Lease Term

 

Renewal

Term

(years)

 

 

McAllen Medical Center

 

$

5,485,000

 

 

December, 2021

 

 

10

 

(a)

Wellington Regional Medical Center

 

$

3,030,000

 

 

December, 2021

 

 

10

 

(b)

Southwest Healthcare System, Inland Valley Campus

 

$

2,648,000

 

 

December, 2021

 

 

10

 

(b)

 

(a)

UHS has two 5-year renewal options at existing lease rates (through 2031).

(b)

UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summarized Financial Information of Equity Affiliates (Tables)
3 Months Ended
Mar. 31, 2018
Equity Method Investments And Joint Ventures [Abstract]  
Limited Liability Companies Accounted for Under Equity Method

 The following property table represents the four LLCs in which we own a noncontrolling interest and were accounted for under the equity method as of March 31, 2018:

 

 

 

 

 

 

 

 

Name of LLC/LP

 

Ownership

 

 

Property Owned by LLC/LP

Suburban Properties

 

 

33

%

 

St. Matthews Medical Plaza II

Brunswick Associates (a.)

 

 

74

%

 

Mid Coast Hospital MOB

Grayson Properties (b.)

 

 

95

%

 

Texoma Medical Plaza

FTX MOB Phase II (c.)

 

 

95

%

 

Forney Medical Plaza II

 

(a.)

This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March 31, 2018.

(b.)

This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018.

(c.)

We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018.  This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March 31, 2018.

Condensed Combined Statements of Income (Unaudited) for Limited Liability Companies Accounted for Under Equity Method

Below are the condensed combined statements of income (unaudited) for the LLCs/LPs accounted for under the equity method during the three months ended March 31, 2018 and 2017.  The three months ended March 31, 2017 include the financial results of Arlington Medical Properties, LLC, through the March 13, 2017 divestiture date.  

 

 

 

Three Months Ended

March 31,

 

 

 

2018

 

 

2017

 

 

 

(amounts in thousands)

 

Revenues

 

$

2,462

 

 

$

3,583

 

Operating expenses

 

 

958

 

 

 

1,250

 

Depreciation and amortization

 

 

457

 

 

 

643

 

Interest, net

 

 

328

 

 

 

562

 

Net income

 

$

719

 

 

$

1,128

 

Our share of net income (a.)

 

$

429

 

 

$

1,077

 

 

(a.)

Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC.   This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.  

 

Condensed Combined Balance Sheets (Unaudited) for LLCs Accounted for Under Equity Method

Below are the condensed combined balance sheets (unaudited) for the four above-mentioned LLCs that were accounted for under the equity method as of March 31, 2018 and December 31, 2017:

 

 

 

March 31,

2018

 

 

December 31,

2017

 

 

 

(amounts in thousands)

 

Net property, including construction in progress

 

$

32,696

 

 

$

33,111

 

Other assets

 

 

3,298

 

 

 

3,560

 

Total assets

 

$

35,994

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Other liabilities

 

$

2,242

 

 

$

3,067

 

Mortgage notes payable, non-recourse to us

 

 

27,693

 

 

 

27,839

 

Equity

 

 

6,059

 

 

 

5,765

 

Total liabilities and equity

 

$

35,994

 

 

$

36,671

 

 

 

 

 

 

 

 

 

 

Investments in LLCs before amounts included in

 

 

 

 

 

 

 

 

   accrued expenses and other liabilities

 

$

4,643

 

 

$

4,671

 

   Amounts included in accrued expenses and other liabilities

 

 

(1,692

)

 

 

(1,895

)

Our share of equity in LLCs, net

 

$

2,951

 

 

$

2,776

 

 

Aggregate Principal Amounts due on Mortgage and Construction Notes Payable by Unconsolidated LLC's Accounted Under Equity Method

As of March 31, 2018, and December 31, 2017, aggregate principal amounts due on mortgage notes payable by unconsolidated LLCs, which are accounted for under the equity method and are non-recourse to us, are as follows (amounts in thousands):

 

 

 

Mortgage Loan Balance (a.)

 

 

 

Name of LLC/LP

 

3/31/2018

 

 

12/31/2017

 

 

Maturity Date

FTX MOB Phase II (5.00% fixed rate mortgage loan)

 

$

5,168

 

 

$

5,202

 

 

October, 2020

Grayson Properties (5.034% fixed rate mortgage loan)

 

 

14,125

 

 

 

14,191

 

 

September, 2021

Brunswick Associates (3.64% fixed rate mortgage loan)

 

 

8,400

 

 

 

8,446

 

 

December, 2024

 

 

$

27,693

 

 

$

27,839

 

 

 

(a.)

All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity. 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recent Accounting Pronouncements (Tables)
3 Months Ended
Mar. 31, 2018
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]  
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents and restricted cash in our Consolidated Balance Sheets to the total amount shown in our Consolidated Statements of Cash Flows:

 

 

 

 

(In thousands)

 

March 31, 2018

 

 

March 31, 2017

 

Cash and cash equivalents

 

$

4,209

 

 

$

4,067

 

Restricted cash

 

 

-

 

 

 

11,253

 

Total Cash, Cash Equivalents and Restricted Cash

 

$

4,209

 

 

$

15,320

 

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt and Financial Instruments (Tables)
3 Months Ended
Mar. 31, 2018
Debt Disclosure [Abstract]  
Summary of Required Compliance Ratios Giving Effect to New Covenants in Credit Agreement

The following table includes a summary of the required compliance ratios, giving effect to the covenants contained in the Credit Agreement (dollar amounts in thousands):

 

 

 

Covenant

 

March 31,

2018

 

Tangible net worth

 

> =$125,000

 

$

191,980

 

Total leverage

 

< 60%

 

 

39.7

%

Secured leverage

 

< 30%

 

 

11.0

%

Unencumbered leverage

 

< 60%

 

 

35.7

%

Fixed charge coverage

 

> 1.50x

 

3.9x

 

 

Outstanding Mortgages, Excluding Net Debt Premium

 

Facility Name

 

Outstanding

Balance

(in thousands) (a.)

 

 

Interest

Rate

 

 

Maturity

Date

Centennial Hills Medical Office Building floating rate

   mortgage loan (b.)

 

$

9,693

 

 

 

4.94

%

 

April, 2018

Rosenberg Children’s Medical Plaza fixed rate

   mortgage loan (c.)

 

 

7,922

 

 

 

4.85

%

 

May, 2018

Vibra Hospital-Corpus Christi fixed rate mortgage loan

 

 

2,599

 

 

 

6.50

%

 

July, 2019

700 Shadow Lane and Goldring MOBs fixed rate

   mortgage loan

 

 

6,010

 

 

 

4.54

%

 

June, 2022

BRB Medical Office Building fixed rate mortgage loan

 

 

6,077

 

 

 

4.27

%

 

December, 2022

Desert Valley Medical Center fixed rate mortgage loan

 

 

4,912

 

 

 

3.62

%

 

January, 2023

2704 North Tenaya Way fixed rate mortgage loan

 

 

6,974

 

 

 

4.95

%

 

November, 2023

Summerlin Hospital Medical Office Building III fixed

   rate mortgage loan

 

 

13,199

 

 

 

4.03

%

 

April, 2024

Tuscan Professional Building fixed rate mortgage loan

 

 

4,397

 

 

 

5.56

%

 

June, 2025

Phoenix Children’s East Valley Care Center fixed rate

   mortgage loan

 

 

9,363

 

 

 

3.95

%

 

January, 2030

Total, excluding net debt premium and net financing fees

 

 

71,146

 

 

 

 

 

 

 

     Less net financing fees

 

 

(652

)

 

 

 

 

 

 

     Plus net debt premium

 

 

287

 

 

 

 

 

 

 

Total mortgages notes payable, non-recourse to us, net

 

$

70,781

 

 

 

 

 

 

 

 

 

(a)

All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.

 

(b)

Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.  

 

(c)

Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.    

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
General - Additional Information (Detail)
Mar. 31, 2018
Property
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
Medical office buildings | Limited Liability Companies  
Organization Consolidation And Presentation Of Financial Statements [Line Items]  
Number of real estate investments 4
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail)
1 Months Ended 3 Months Ended
Apr. 30, 2017
Time
Mar. 31, 2018
USD ($)
Property
Time
Mar. 31, 2017
USD ($)
Dec. 31, 2017
Related Party Transaction [Line Items]        
Annual advisory fee as percentage of average invested real estate assets   0.70%    
Advisory fee   $ 904,000 $ 866,000  
Universal Health Services, Inc        
Related Party Transaction [Line Items]        
Number of term renewal options | Time   6    
Additional renewal terms   5 years    
Number of medical office buildings and free standing emergency departments | Property   17    
Option to renew lease, notice period prior to termination date of current term   90 days    
Period to purchase respective leased facilities at same price after lease terms   180 days    
Renewal period of respective leased facilities at same price after lease terms   180 days    
Number of renewal options at existing lease rates | Time   3    
Percentage ownership of outstanding shares   5.70%   5.70%
Universal Health Services, Inc | Henderson Medical Plaza        
Related Party Transaction [Line Items]        
Number of term renewal options | Time 2      
Additional renewal terms 10 years      
Ground lease agreement period 75 years      
Amount invested in MOB under construction   $ 12,800,000    
Universal Health Services, Inc | Customer Concentration Risk | Revenues        
Related Party Transaction [Line Items]        
Percentage of revenues generated from leases and tenants   22.00% 23.00%  
Universal Health Services, Inc | Customer Concentration Risk | Revenues | Tenants        
Related Party Transaction [Line Items]        
Percentage of revenues generated from leases and tenants   31.00% 31.00%  
Universal Health Services, Inc | Hospital Facilities Leased        
Related Party Transaction [Line Items]        
Number of hospital facilities leased | Property   3    
Universal Health Services, Inc | Minimum        
Related Party Transaction [Line Items]        
Initial lease terms   13 years    
Universal Health Services, Inc | Maximum        
Related Party Transaction [Line Items]        
Initial lease terms   15 years    
Universal Health Services of Delaware Inc        
Related Party Transaction [Line Items]        
Annual incentive fee to Advisor as percentage of cash available for distribution   20.00%    
Incentive fees   $ 0 $ 0  
Advisory fee   904,000 866,000  
Average invested real estate assets   $ 517,000,000 $ 495,000,000  
Universal Health Services of Delaware Inc | Minimum        
Related Party Transaction [Line Items]        
Percentage of equity to be exceeded for incentive distribution   15.00%    
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail)
3 Months Ended
Mar. 31, 2018
USD ($)
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 5,485,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [1]
Wellington Regional Medical Center  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 3,030,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [2]
Southwest Healthcare System, Inland Valley Campus  
Operating Leased Assets [Line Items]  
Annual Minimum Rent $ 2,648,000
End of Lease Term 2021-12
Renewal Term (years) 10 years [2]
[1] UHS has two 5-year renewal options at existing lease rates (through 2031).
[2] UHS has two 5-year renewal options at fair market value lease rates (2022 through 2031).
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) - Universal Health Services, Inc
3 Months Ended
Mar. 31, 2018
Time
RenewalOption
Operating Leased Assets [Line Items]  
Number of renewal options at existing lease rates 3
McAllen Medical Center  
Operating Leased Assets [Line Items]  
Number of renewal options at existing lease rates 2
Renewal options term at existing lease rates 5 years
Renewal options at existing lease rates expiration year 2031
Wellington Regional Medical Center And Southwest Healthcare System  
Operating Leased Assets [Line Items]  
Number of renewal options at fair market value lease rates | RenewalOption 2
Renewal options term at fair market value lease rates 5 years
Wellington Regional Medical Center And Southwest Healthcare System | Minimum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2022
Wellington Regional Medical Center And Southwest Healthcare System | Maximum  
Operating Leased Assets [Line Items]  
Renewal options at fair market value lease rates expiration year 2031
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
Dividends - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Equity [Abstract]    
Dividends payable $ 9,134  
Declared dividends, per share $ 0.665  
Dividends declared and paid   $ 8,907
Declared and paid dividends, per share   $ 0.655
Dividends payable, date to be paid Apr. 02, 2018  
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions and Dispositions - Additional Information (Detail)
1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
Acquisition
Mar. 31, 2017
USD ($)
Acquisition
Sep. 30, 2017
USD ($)
Mar. 12, 2017
Business Acquisitions And Dispositions [Line Items]          
Number of acquisitions | Acquisition   0 0    
Cash received from dispositions   $ 0 $ 53,967,000    
Repayment of loan     21,400,000    
St. Mary's Professional Office Building          
Business Acquisitions And Dispositions [Line Items]          
Net cash proceeds received from divestiture $ 57,300,000   57,300,000    
Net sale proceeds due       $ 11,300,000  
Gain on divestiture of property     $ 27,200,000    
Arlington Medical Properties          
Business Acquisitions And Dispositions [Line Items]          
Ownership prior to minority interest purchase 85.00%   85.00%    
Remaining percentage owned by third party member         15.00%
Total purchase price $ 7,900,000        
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summarized Financial Information of Equity Affiliates - Additional Information (Detail)
3 Months Ended
Mar. 31, 2018
Property
Limited Liability Companies | Medical office buildings  
Schedule Of Equity Method Investments [Line Items]  
Number of real estate investments 4
Minimum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 60 days
Maximum  
Schedule Of Equity Method Investments [Line Items]  
Number of days for Non-Offering Member either to purchase or sell its entire ownership interest to or from Offering Member 90 days
4 Unconsolidated Limited Liability Companies / Limited Partner | Minimum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 33.00%
4 Unconsolidated Limited Liability Companies / Limited Partner | Maximum  
Schedule Of Equity Method Investments [Line Items]  
Non-controlling equity interest, ownership percentage 95.00%
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
Limited Liability Companies Accounted for Under Equity Method (Detail) - Equity Method Investments
3 Months Ended
Mar. 31, 2018
Suburban Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 33.00%
Property Owned by LLC/LP St. Matthews Medical Plaza II
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Ownership 74.00% [1]
Property Owned by LLC/LP Mid Coast Hospital MOB [1]
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [2]
Property Owned by LLC/LP Texoma Medical Plaza [2]
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Ownership 95.00% [3]
Property Owned by LLC/LP Forney Medical Plaza II [3]
[1] This LLC has a third-party term loan, which is non-recourse to us, of $8.4 million outstanding as of March 31, 2018.
[2] This building is on the campus of a UHS hospital and has tenants that include subsidiaries of UHS. This LP has a third-party term loan, which is non-recourse to us, of $14.1 million outstanding as of March 31, 2018.
[3] We have committed to invest up to $2.5 million in equity and debt financing, of which $2.1 million has been funded as of March 31, 2018. This LP has a third-party term loan, which is non-recourse to us, of $5.2 million outstanding as of March 31, 2018.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail)
$ in Millions
Mar. 31, 2018
USD ($)
Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan $ 8.4
Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan 14.1
FTX MOB Phase II limited partnership  
Schedule Of Equity Method Investments [Line Items]  
Third-party term loan 5.2
Committed investment in equity and debt financing, funded 2.1
Commitment to investment $ 2.5
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Equity Method Investments And Joint Ventures [Abstract]    
Revenues $ 2,462 $ 3,583
Operating expenses 958 1,250
Depreciation and amortization 457 643
Interest, net 328 562
Net income 719 1,128
Our share of net income [1] $ 429 $ 1,077
[1] Our share of net income for the three months ended March 31, 2017 includes approximately $284,000 of interest income earned by us on an advance made to Arlington Medical Properties, LLC. This advance was repaid to us effective with the previously mentioned Arlington Medical Properties, LLC transaction during March, 2017, therefore there was no interest income earned by us on this advance subsequent to March, 2017.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Arlington Medical Properties    
Schedule Of Equity Method Investments [Line Items]    
Interest income earned on various advances made to LLCs $ 0 $ 284,000
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Equity Method Investments And Joint Ventures [Abstract]    
Net property, including construction in progress $ 32,696 $ 33,111
Other assets 3,298 3,560
Total assets 35,994 36,671
Other liabilities 2,242 3,067
Mortgage notes payable, non-recourse to us 27,693 27,839
Equity 6,059 5,765
Total liabilities and equity 35,994 36,671
Investments in LLCs before amounts included in accrued expenses and other liabilities 4,643 4,671
Amounts included in accrued expenses and other liabilities (1,692) (1,895)
Our share of equity in LLCs, net $ 2,951 $ 2,776
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance $ 27,693 $ 27,839
Equity Method Investments    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] 27,693 27,839
Equity Method Investments | FTX MOB Phase II    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 5,168 5,202
Maturity Date 2020-10  
Equity Method Investments | Grayson Properties    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 14,125 14,191
Maturity Date 2021-09  
Equity Method Investments | Brunswick Associates    
Schedule Of Equity Method Investments [Line Items]    
Mortgage Loan Balance [1] $ 8,400 $ 8,446
Maturity Date 2024-12  
[1] All mortgage loans require monthly principal payments through maturity and include a balloon principal payment upon maturity
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail)
Mar. 31, 2018
5.00% Fixed Rate Mortgage Loan | FTX MOB Phase II  
Schedule Of Equity Method Investments [Line Items]  
Loan interest rate fixed percentage 5.00%
5.034% Fixed Rate Mortgage Loan | Grayson Properties  
Schedule Of Equity Method Investments [Line Items]  
Loan interest rate fixed percentage 5.034%
3.64% Fixed Rate Mortgage Loan | Brunswick Associates  
Schedule Of Equity Method Investments [Line Items]  
Loan interest rate fixed percentage 3.64%
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) - USD ($)
$ in Thousands
Mar. 31, 2018
Dec. 31, 2017
Mar. 31, 2017
Dec. 31, 2016
New Accounting Pronouncements And Changes In Accounting Principles [Abstract]        
Cash and cash equivalents $ 4,209 $ 3,387 $ 4,067  
Restricted cash     11,253  
Total Cash, Cash Equivalents and Restricted Cash $ 4,209 $ 3,387 $ 15,320 $ 3,930
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
Recent Accounting Pronouncements - Additional Information (Detail) - Topic 606 - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
New Accounting Pronouncements Or Change In Accounting Principle [Line Items]    
Cumulative adjustment $ 0  
Tenant reimbursement and other property income 2,700,000 $ 2,400,000
Contract assets 0  
Contract liabilities $ 0  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
Debt and Financial Instruments - Additional Information (Detail)
3 Months Ended 21 Months Ended 24 Months Ended
May 09, 2018
USD ($)
MortgageLoan
Mar. 27, 2018
USD ($)
Option
Feb. 13, 2018
USD ($)
Mar. 31, 2018
USD ($)
MortgageLoan
Mar. 31, 2017
USD ($)
Sep. 30, 2016
USD ($)
Derivative
Jun. 30, 2016
USD ($)
Derivative
Mar. 31, 2018
USD ($)
MortgageLoan
Mar. 31, 2018
USD ($)
MortgageLoan
Dec. 31, 2017
USD ($)
MortgageLoan
Debt Instrument [Line Items]                    
Outstanding borrowings under revolving credit agreement       $ 175,000,000       $ 175,000,000 $ 175,000,000 $ 181,050,000
Outstanding borrowings under letter of credit       1,500,000       1,500,000 1,500,000  
Available borrowing capacity       123,500,000       $ 123,500,000 $ 123,500,000  
Repayments of mortgage loan       $ 4,596,000 $ 11,174,000          
Number of non-recourse mortgages | MortgageLoan       10       10 10 11
Mortgage loan fair value       $ 71,100,000       $ 71,100,000 $ 71,100,000 $ 76,300,000
Balance of Non Recourse Mortgages       71,146,000 [1]       71,146,000 [1] 71,146,000 [1] $ 75,700,000
Interest Rate Cap                    
Debt Instrument [Line Items]                    
Number of interest rate cap agreements | Derivative           1 1      
Notional amount           $ 30,000,000 $ 30,000,000      
Premium paid           $ 55,000 $ 115,000      
Expiration date of interest rate cap           Mar. 31, 2019 Mar. 31, 2019      
Derivative interest rate cap, payment received from counterparties               7,500 7,500  
Sparks Medical Building/Vista Medical Terrace Floating Rate Mortgage Loan                    
Debt Instrument [Line Items]                    
Repayments of mortgage loan     $ 4,100,000              
Subsequent Event                    
Debt Instrument [Line Items]                    
Repayments of mortgage loan $ 17,600,000                  
Number of non-recourse mortgages | MortgageLoan 2                  
LIBOR | Interest Rate Cap                    
Debt Instrument [Line Items]                    
Derivative instruments, LIBOR rate           1.50% 1.50%      
Credit Agreement                    
Debt Instrument [Line Items]                    
Outstanding borrowing   $ 300,000,000   $ 300,000,000       $ 300,000,000 $ 300,000,000  
Increase in borrowing capacity   $ 50,000,000                
Unsecured revolving amended credit agreement terminated date   2022-03                
Number of additional six month extension options | Option   2                
Proceeds from Lines of Credit   $ 50,000,000                
Credit facility, Interest Rate Terms       one, two, three, or six month LIBOR plus an applicable margin ranging from 1.10% to 1.35% or at the Base Rate plus an applicable margin ranging from 0.10% to 0.35%.            
Base rate description       the greater of: (a) the administrative agent’s prime rate; (b) the federal funds effective rate plus 1/2 of 1%, and; (c) one month LIBOR plus 1%.            
Facility fee payable on commitment       0.20%            
Credit Agreement | LIBOR                    
Debt Instrument [Line Items]                    
Margin points added to the reference rate       1.20%            
Credit Agreement | Base Rate                    
Debt Instrument [Line Items]                    
Margin points added to the reference rate       0.20%            
Credit Agreement | Swingline/Short-Term Loans                    
Debt Instrument [Line Items]                    
Outstanding borrowing   30,000,000                
Credit Agreement | Letters of Credit                    
Debt Instrument [Line Items]                    
Outstanding borrowing   $ 40,000,000                
Credit Agreement | Minimum                    
Debt Instrument [Line Items]                    
Facility fee payable on commitment   0.15%                
Credit Agreement | Minimum | LIBOR                    
Debt Instrument [Line Items]                    
Margin points added to the reference rate   1.10%                
Margin points added to the base rate   1.00%                
Credit Agreement | Minimum | Base Rate                    
Debt Instrument [Line Items]                    
Margin points added to the reference rate   0.10%                
Credit Agreement | Minimum | Federal Funds Effective Rate                    
Debt Instrument [Line Items]                    
Margin points added to the base rate   0.50%                
Credit Agreement | Maximum                    
Debt Instrument [Line Items]                    
Facility fee payable on commitment   0.35%                
Credit Agreement | Maximum | LIBOR                    
Debt Instrument [Line Items]                    
Margin points added to the reference rate   1.35%                
Credit Agreement | Maximum | Base Rate                    
Debt Instrument [Line Items]                    
Margin points added to the reference rate   0.35%                
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail)
$ in Thousands
3 Months Ended
Mar. 31, 2018
USD ($)
Debt Instrument [Line Items]  
Covenant, Tangible net worth $ 125,000
Tangible net worth $ 191,980
Total leverage 39.70%
Secured leverage 11.00%
Unencumbered leverage 35.70%
Fixed charge coverage 3.90%
Maximum  
Debt Instrument [Line Items]  
Covenant, Total leverage 60.00%
Covenant, Secured leverage 30.00%
Covenant, Unencumbered leverage 60.00%
Minimum  
Debt Instrument [Line Items]  
Covenant, Fixed charge coverage 1.50%
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Dec. 31, 2017
Debt Instrument [Line Items]    
Outstanding Balance $ 71,146 [1] $ 75,700
Less net financing fees [1] (652)  
Plus net debt premium [1] 287  
Total mortgages notes payable, non-recourse to us, net 70,781 [1] $ 75,359
Centennial Hills Medical Office Building floating rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1],[2] $ 9,693  
Debt Instrument Interest Rate Stated Percentage [2] 4.94%  
Maturity Date [2] 2018-04  
Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1],[3] $ 7,922  
Debt Instrument Interest Rate Stated Percentage [3] 4.85%  
Maturity Date [3] 2018-05  
Vibra Hospital-Corpus Christi fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 2,599  
Debt Instrument Interest Rate Stated Percentage 6.50%  
Maturity Date 2019-07  
700 Shadow Lane and Goldring MOBs fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,010  
Debt Instrument Interest Rate Stated Percentage 4.54%  
Maturity Date 2022-06  
BRB Medical Office Building fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,077  
Debt Instrument Interest Rate Stated Percentage 4.27%  
Maturity Date 2022-12  
Desert Valley Medical Center Floating Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,912  
Debt Instrument Interest Rate Stated Percentage 3.62%  
Maturity Date 2023-01  
2704 North Tenaya Way fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 6,974  
Debt Instrument Interest Rate Stated Percentage 4.95%  
Maturity Date 2023-11  
Summerlin Hospital Medical Office Building III fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 13,199  
Debt Instrument Interest Rate Stated Percentage 4.03%  
Maturity Date 2024-04  
Tuscan Professional Building fixed rate mortgage loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 4,397  
Debt Instrument Interest Rate Stated Percentage 5.56%  
Maturity Date 2025-06  
Phoenix Children's East Valley Care Center Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Outstanding Balance [1] $ 9,363  
Debt Instrument Interest Rate Stated Percentage 3.95%  
Maturity Date 2030-01  
[1] All mortgage loans require monthly principal payments through maturity and either fully amortize or include a balloon principal payment upon maturity.
[2] Upon its maturity, this $9.7 million floating rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.
[3] Upon its maturity, this $7.9 million fixed rate mortgage loan was fully repaid utilizing borrowings under our Credit Agreement.
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
Summary of Outstanding Mortgages, Excluding Net Debt Premium (Parenthetical) (Detail) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Debt Instrument [Line Items]    
Repayments of mortgage loan $ 4,596 $ 11,174
Centennial Hills Medical Office Building floating rate mortgage loan    
Debt Instrument [Line Items]    
Repayments of mortgage loan 9,700  
Rosenberg Children's Medical Plaza Fixed Rate Mortgage Loan    
Debt Instrument [Line Items]    
Repayments of mortgage loan $ 7,900  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting - Additional Information (Detail)
3 Months Ended
Mar. 31, 2018
Segment
Segment Reporting [Abstract]  
Number of reportable segments 1
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
Impact of Hurricane Harvey - Additional Information (Detail)
3 Months Ended 4 Months Ended 7 Months Ended
Mar. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Mar. 31, 2018
USD ($)
Aug. 31, 2017
Building
Unusual Or Infrequent Item [Line Items]        
Hurricane related insurance recoveries $ 968,000      
Hurricane insurance recoveries in excess of property damage write-downs 4,535,000      
Hurricane Harvey, Extensive Water Damage | Houston, Texas        
Unusual Or Infrequent Item [Line Items]        
Number of medical office buildings | Building       5
Hurricane Harvey        
Unusual Or Infrequent Item [Line Items]        
Additional insurance recovery proceeds 5,500,000      
Hurricane related insurance recoveries 12,500,000      
Hurricane Harvey | Business Interruption        
Unusual Or Infrequent Item [Line Items]        
Hurricane related insurance recoveries     $ 968,000  
Hurricane insurance recoveries in excess of property damage write-downs $ 4,500,000      
Hurricane Harvey | 2017 business interruption        
Unusual Or Infrequent Item [Line Items]        
Hurricane related insurance recoveries   $ 500,000    
Properties Damaged and Closed from Hurricane Harvey | Spring, Texas | Cypresswood Professional Center        
Unusual Or Infrequent Item [Line Items]        
Number of medical office buildings | Building       2
Properties Damaged and Closed from Hurricane Harvey | Kingwood, Texas | Professional Buildings at Kings Crossing        
Unusual Or Infrequent Item [Line Items]        
Number of medical office buildings | Building       2
Properties Damaged and Closed from Hurricane Harvey | Kingwood, Texas | Kelsey-Seybold Clinic at Kings Crossing        
Unusual Or Infrequent Item [Line Items]        
Number of medical office buildings | Building       1
EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 56 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 128 219 1 true 62 0 false 13 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.uhrit.com/20180331/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.uhrit.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.uhrit.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.uhrit.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.uhrit.com/20180331/taxonomy/role/StatementCondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statement of Cash Flows Sheet http://www.uhrit.com/20180331/taxonomy/role/StatementCondensedConsolidatedStatementOfCashFlows Condensed Consolidated Statement of Cash Flows Statements 6 false false R7.htm 100060 - Disclosure - General Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureGeneral General Notes 7 false false R8.htm 100070 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions Notes 8 false false R9.htm 100080 - Disclosure - Dividends Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureDividends Dividends Notes 9 false false R10.htm 100090 - Disclosure - Acquisitions and Dispositions Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureAcquisitionsAndDispositions Acquisitions and Dispositions Notes 10 false false R11.htm 100100 - Disclosure - Summarized Financial Information of Equity Affiliates Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates Summarized Financial Information of Equity Affiliates Notes 11 false false R12.htm 100110 - Disclosure - Recent Accounting Pronouncements Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements Recent Accounting Pronouncements Notes 12 false false R13.htm 100120 - Disclosure - Debt and Financial Instruments Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureDebtAndFinancialInstruments Debt and Financial Instruments Notes 13 false false R14.htm 100130 - Disclosure - Segment Reporting Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 14 false false R15.htm 100140 - Disclosure - Impact of Hurricane Harvey Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureImpactOfHurricaneHarvey Impact of Hurricane Harvey Notes 15 false false R16.htm 100150 - Disclosure - Recent Accounting Pronouncements (Policies) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncementsPolicies Recent Accounting Pronouncements (Policies) Policies http://www.uhrit.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements 16 false false R17.htm 100160 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions (Tables) Tables http://www.uhrit.com/20180331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactions 17 false false R18.htm 100170 - Disclosure - Summarized Financial Information of Equity Affiliates (Tables) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesTables Summarized Financial Information of Equity Affiliates (Tables) Tables http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliates 18 false false R19.htm 100180 - Disclosure - Recent Accounting Pronouncements (Tables) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncementsTables Recent Accounting Pronouncements (Tables) Tables http://www.uhrit.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncements 19 false false R20.htm 100190 - Disclosure - Debt and Financial Instruments (Tables) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsTables Debt and Financial Instruments (Tables) Tables http://www.uhrit.com/20180331/taxonomy/role/DisclosureDebtAndFinancialInstruments 20 false false R21.htm 100200 - Disclosure - General - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureGeneralAdditionalInformationDetail General - Additional Information (Detail) Details 21 false false R22.htm 100210 - Disclosure - Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Services, Inc. ("UHS") and Related Party Transactions - Additional Information (Detail) Details http://www.uhrit.com/20180331/taxonomy/role/DisclosureRelationshipWithUniversalHealthServicesIncUHSAndRelatedPartyTransactionsTables 22 false false R23.htm 100220 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Detail) Details 23 false false R24.htm 100230 - Disclosure - Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureExistingLeaseTermsAndRenewalOptionsForEachOfUHSHospitalFacilitiesParentheticalDetail Existing Lease Terms and Renewal Options for Each of UHS Hospital Facilities (Parenthetical) (Detail) Details 24 false false R25.htm 100240 - Disclosure - Dividends - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureDividendsAdditionalInformationDetail Dividends - Additional Information (Detail) Details 25 false false R26.htm 100250 - Disclosure - Acquisitions and Dispositions - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureAcquisitionsAndDispositionsAdditionalInformationDetail Acquisitions and Dispositions - Additional Information (Detail) Details 26 false false R27.htm 100260 - Disclosure - Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummarizedFinancialInformationOfEquityAffiliatesAdditionalInformationDetail Summarized Financial Information of Equity Affiliates - Additional Information (Detail) Details 27 false false R28.htm 100270 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodDetail Limited Liability Companies Accounted for Under Equity Method (Detail) Details 28 false false R29.htm 100280 - Disclosure - Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureLimitedLiabilityCompaniesAccountedForUnderEquityMethodParentheticalDetail Limited Liability Companies Accounted for Under Equity Method (Parenthetical) (Detail) Details 29 false false R30.htm 100290 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Detail) Details 30 false false R31.htm 100300 - Disclosure - Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureCondensedCombinedStatementOfIncomeForLimitedLiabilitiesAccountedForUnderEquityMethodParentheticalDetail Condensed Combined Statement of Income for Limited Liabilities Accounted for under Equity Method (Parenthetical) (Detail) Details 31 false false R32.htm 100310 - Disclosure - Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureCondensedCombinedBalanceSheetsOfLimitedLiabilitiesAccountedForUnderEquityMethodDetail Condensed Combined Balance Sheets of Limited Liabilities Accounted for under Equity Method (Detail) Details 32 false false R33.htm 100320 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Notes http://www.uhrit.com/20180331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcsAccountedUnderEquityMethodDetail Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Detail) Details 33 false false R34.htm 100330 - Disclosure - Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail) Notes http://www.uhrit.com/20180331/taxonomy/role/DisclosureAggregatePrincipalAmountsDueOnMortgageNotesPayableByUnconsolidatedLlcsAccountedUnderEquityMethodParentheticalDetail Aggregate Principal Amounts Due on Mortgage Notes Payable by Unconsolidated LLCs, Accounted Under Equity Method (Parenthetical) (Detail) Details 34 false false R35.htm 100340 - Disclosure - Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureScheduleOfReconciliationOfCashCashEquivalentsAndRestrictedCashDetail Schedule of Reconciliation of Cash, Cash Equivalents and Restricted Cash (Detail) Details 35 false false R36.htm 100350 - Disclosure - Recent Accounting Pronouncements - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureRecentAccountingPronouncementsAdditionalInformationDetail Recent Accounting Pronouncements - Additional Information (Detail) Details 36 false false R37.htm 100360 - Disclosure - Debt and Financial Instruments - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureDebtAndFinancialInstrumentsAdditionalInformationDetail Debt and Financial Instruments - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummaryOfRequiredComplianceRatiosInConnectionWithTermsOfCreditAgreementDetail Summary of Required Compliance Ratios in Connection with Terms of Credit Agreement (Detail) Details 38 false false R39.htm 100380 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Detail) Details 39 false false R40.htm 100390 - Disclosure - Summary of Outstanding Mortgages, Excluding Net Debt Premium (Parenthetical) (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSummaryOfOutstandingMortgagesExcludingNetDebtPremiumParentheticalDetail Summary of Outstanding Mortgages, Excluding Net Debt Premium (Parenthetical) (Detail) Details 40 false false R41.htm 100400 - Disclosure - Segment Reporting - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetail Segment Reporting - Additional Information (Detail) Details 41 false false R42.htm 100410 - Disclosure - Impact of Hurricane Harvey - Additional Information (Detail) Sheet http://www.uhrit.com/20180331/taxonomy/role/DisclosureImpactOfHurricaneHarveyAdditionalInformationDetail Impact of Hurricane Harvey - Additional Information (Detail) Details 42 false false All Reports Book All Reports uht-20180331.xml uht-20180331.xsd uht-20180331_cal.xml uht-20180331_def.xml uht-20180331_lab.xml uht-20180331_pre.xml http://fasb.org/us-gaap/2017-01-31 http://xbrl.sec.gov/dei/2014-01-31 http://xbrl.sec.gov/invest/2013-01-31 true true ZIP 60 0001564590-18-012426-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-18-012426-xbrl.zip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end